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Abstract 
 
The purpose of this study was to elucidate the role of chlamydial 60 kDa heat shock protein 
(CHSP60) induced cell-mediated immune (CMI) response in women with tubal factor infertility 
(TFI). Chlamydia trachomatis is the major cause of sexually transmitted bacterial infections (STIs) 
worlwide. Most chlamydial infections are asymptomatic or show mild symptoms and are thus often 
left untreated. Reinfections with same or different serovars are common. The long-term 
consequences of recurrent or persistent chlamydial infections are severe leading to structural 
damage of the inflamed tissue. Chronic C. trachomatis infection in women has been linked with 
ectopic pregnancy and TFI. Animal models for chlamydial infections have shown that CD4+ T-
cells are the key players both in resolution of and protection from chlamydial infection, but have 
been implicated also in the pathogenesis of the disease sequelae. Generation of pathologic changes 
in the fallopian tube tissue is mostly an unknown process but is thought to be due to repeated or 
persistent infections. In addition, a balance of pro- and anti-inflammatory cytokines, especially that 
of interferon-gamma (IFN-) and interleukin-10 (IL-10) may have an important role during both 
primary and recurrent or persistent infection. 
We established C. trachomatis-specific T-lymphocyte lines (TLLs) and T-lymphocyte clones 
(TLCs) from the obstructed fallopian tube tissue specimens of infertile women (TFI) and from 
endometrial biopsies of patients with acute pelvic inflammatory disease. CMI responses of isolated 
T-cells in response to chlamydial elementary body (EB) antigens and CHSP60 were measured 
using lymphocyte proliferation (LP) assay. Frequency of CHSP60-responding T-cells was 
determined. Production of pro-inflammatory (IFN-) and anti-inflammatory (IL-10) cytokines by 
the Chlamydia-specific TLLs and TLCs in response to recall antigens was determined. 
According to our results C. trachomatis-specific T-cells were frequently found in peripheral 
blood and in the inflamed fallopian tube tissue of TFI patients. One third of the T-cells derived 
from fallopian tube tissue specimens of TFI patients responded to CHSP60. We also found that 
CHSP60-specific T-cells produce IL-10 which may down-regulate appropriate IFN--mediated 
immune response needed for elimination of chlamydial infection. In addition, the CHSP60-specific 
CMI response was associated with HLA-DQA1*0102 and HLA-DQB1*0602 alleles and IL-10 –
1082 AA genotype in the TFI patients. 
Taken together, these data suggest that the etiopathogenesis of C. trachomatis-related TFI is 
associated with impaired CMI response caused by CHSP60-reactive T-cells. Larger clinical and 
population-based follow-up studies are warranted to further evaluate the role of specific HLA class 
II and IL-10 geno(haplo)types in association with CHSP60-reactive T-cells in the pathogenesis of 
TFI. 
 
Keywords: Chlamydia trachomatis, heat shock protein, tubal factor infertility (TFI), cell-mediated 
immunity (CMI) 
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 Abbreviations 
 
APC   Antigen presenting cell 
ATP   Adenosine triphosphate 
bp   base pair 
CMI   Cell-mediated immunity/ immune response 
(C)HSP60  60 kDa (chlamydial) heat shock protein 
CTL   Cytotoxic T lymphocyte/ CD8+ T cell 
DFA   Direct fluorescence assay 
DNA   Deoxyribonucleic acid 
DTH   Delayed type hypersensitivity 
EB   Elementary body 
ELISA   Enzyme-linked immunosorbent assay 
HLA   Human leukocyte antigen 
HSP   Heat-shock protein 
IFN-   Interferon-gamma 
Ig   Immunoglobulin 
IL   Interleukin 
LCR   Ligase chain reaction 
LGV   Lymphogranuloma venereum 
LP   Lymphocyte proliferation 
LPS   Lipopolysaccharide 
MHC   Major histocompatibility complex 
MIF   Micro-immunofluorescence 
MOMP/OmpA  Major outer membrane protein 
NK cell   Natural killer cell 
OMP2/OmcB  60 kDa cysteine-rich outer membrane protein  
OMP3/OmcA  12 kDa outer membrane protein 
PBL   Peripheral blood lymphocyte 
PCR   Polymerase chain reaction 
PHA   Phytohemagglutinine 
PID   Pelvic inflammatory disease 
Pomp/Pmp Putative/ polymorphic outer membrane protein 
PWM Pokeweed mitogen 
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RA   Rheumatoid arthritis 
ReA   Reactive arthritis 
RB   Reticulate body 
(r)RNA   (ribosomal) ribonucleic acid 
SI   Stimulation index 
TFI   Tubal factor infertility 
TLC   T lymphocyte (cell) clone 
TLL   T lymphocyte (cell) line 
TNF   Tumour necrosis factor  
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1 Introduction 
Chlamydia trachomatis infection is the most common bacterial sexually transmitted 
disease worldwide. It has been estimated that about 90 million new infections occur 
annually. Most of the acute infections are asymptomatic and are thus left untreated. 
Reinfections with the same or different serovar are common because C. trachomatis 
immunity is short-lived and usually serovar-specific. In some women repeated or 
persistent C. trachomatis infection leads to scarring of the fallopian tube tissue and 
subsequent infertility because of occlusion of the tubes. In fact, C. trachomatis-associated 
tubal factor infertility (TFI) is one of the top three reasons for couples to seek help for 
involuntary infertility. 
Chlamydiae are typical intracellular bacteria that are able to elicit a variety of humoral 
and cell-mediated immune (CMI) responses. Interplay between humoral and CMI 
responses in terms of protection or adverse sequelae of chlamydial infection, is not 
thoroughly studied. For a long period of time antibodies were considered to play the main 
role to confer protection. Trachoma vaccine trials in the 1960s and 1970s showed that 
some protective immunity develops following primary chlamydial infection, but it is 
short-lived and a different serovar can infect the individual shortly after resolution of the 
primary infection (Grayston and Wang 1978). It is probable that “protection” detected in 
these studies was mediated by antibodies. The duration of chlamydial ocular infection is 
shorter and the resolution of disease is more rapid in older individuals compared to 
children indicating that some kind of immunity develops over time (Bailey et al. 1999). 
Immunity during chronic chlamydial infections is still at large a mystery although 
persistent or repeated infections are needed to pave the way to immunopathological 
changes. Until 1990s the only role of CMI was thought to be “the bad guy” eliciting 
pathological changes seen in repeatedly (persistently) infected individuals. Since then 
convincing amount of evidence has gathered suggesting that CMI is needed to eliminate 
chlamydial infection and also for protection. Recovery from chlamydial infections results 
from type 1 immune response (see 2.6.1) that is largely regulated by interferon-gamma 
(IFN. What may be even more important is the balance of pro- and anti-inflammatory 
cytokines present at the site of infection. Chronic chlamydial infection may induce 
continuous inflammatory reactions through the action of secreted cytokines that provoke 
tissue injury. Serological studies with humans have suggested that one protein in 
particular, i.e. the 60 kDa chlamydial heat shock protein (CHSP60) may have a central 
14 
role in the pathogenesis of chlamydial infection. Experimental murine and primate 
models of chronic chlamydial disease have further supported a role for CHSP60 since 
repeated exposure to CHSP60 elicited delayed-type hypersensitivity (DTH) reactions and 
scarring in animals previously immunized with C. trachomatis. In human chlamydial 
infections especially in the TFI the role of CHSP60 in eliciting and maintaining 
inflammatory response in the tissue is not known. 
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2 Review of the literature 
2.1  Chlamydia 
Chlamydiae are obligate intracellular gram-negative-like bacteria that replicate in 
membrane-bound vacuoles (inclusions) in the cytoplasm of eukaryotic cells (reviewed by 
Ward 1983, Matsumoto 1988, and Ward 1988). They belong to the order Chlamydiales, 
which contains one family, Chlamydiaceae with one genus Chlamydia (Moulder et al. 
1984, Fukushi and Hirai 1992, Pudjiatmoko et al. 1997). The genus is divided into four 
species, C. trachomatis, C. pneumoniae, C. psittaci and C. pecorum, which differ in their 
host cell tropism, but have similar cell structure and share certain biological properties in 
the course of their intracellular existence (reviewed by Hackstadt 1999). Recent discovery 
of new obligate intracellular organisms that have Chlamydia-like developmental cycle 
and analysis of the ribosomal operon lead Everett et al. (1999) to propose a new revised 
taxonomy to Chlamydiaceae. The new taxonomy is based on phylogenetic analyses of 
16S and 23S rRNA genes corroborated with genetic and phenotypic information obtained 
during the past few years (Kaltenboeck et al. 1993, Everett and Andersen 1997, 
Pudjiatmoko et al. 1997, Takahashi et al. 1997). According to the proposed taxonomy the 
family Chlamydiaceae is divided into two genera, Chlamydia and Chlamydophila (Figure 
1) with nine species (Everett et al. 1999). The new taxonomy, however, has not yet gained 
general acceptance (Schachter et al. 2001). 
Chlamydiae cause infections both in humans and in animals. They spread by aerosol 
or by contact (reviewed by Bavoil et al. 1996) and have been demonstrated in vitro to 
infect and multiply in wide variety of cells including epithelial and endothelial cells. In 
addition, chlamydiae are able to infect and/or get into and remain viable in phagocytes, 
macrophages and monocytes (reviewed by Bavoil et al. 1996). This gives the organism an 
opportunity to disseminate from the original site of infection. Past studies focused mainly 
on infections caused by C. trachomatis but during the last decade C. pneumoniae has also 
been under keen investigation because of its association with the pathogenesis of 
cardiovascular disease (reviewed by Saikku 2000b, Saikku 2000a). 
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Old taxonomy    New taxonomy 
 
Order:   Chlamydiales 
 
 
Family:   Chlamydiaceae 
 
 
Genus: Chlamydia   Chlamydia Chlamydophila 
 
 
Species: C. trachomatis   C. trachomatis C. pneumoniae 
 
 
  C. pneumoniae   C. muridarum C. psittaci 
 
 
  C. psittaci   C. suis  C. pecorum 
 
 
  C. pecorum     C. caviae 
 
 
        C. abortus 
 
 
        C. felis 
 
Fig. 1. Old and new taxonomy of chlamydiae (modified from Everett et al. 1999). 
 
2.2  Developmental cycle of chlamydiae 
Chlamydiae have a unique developmental cycle comprising two functionally and 
morphologically different forms to survive both outside and inside the host cell. The 
elementary body (EB) is the infectious form of the bacterium. It attaches to and enters 
into the host cell. EB is a small particle (Ø 300 –400 nm) with a rigid cell wall, which 
contains the major outer membrane protein (MOMP) and two cysteine-rich outer 
membrane proteins, OMP2 and OMP3 as well as other proteins (reviewed by Beatty et al. 
1994c). EB cell wall does not have the kind of peptidoglycan that other gram-negative 
bacteria have (Barbour et al. 1982) although chlamydiae encode proteins forming a 
nearly complete peptidoglycan synthesis pathway (reviewed by Rockey et al. 2000). It 
has been proposed that chlamydiae synthesize a truncated form of peptidoglycan that 
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cannot be detected by conventional methods (Ghuysen and Goffin 1999). This could 
explain why in vitro chlamydiae are sensitive to drugs that inhibit peptidoglycan synthesis 
(Moulder 1993), such as penicillin. 
The structure of EB makes it resistant to environmental factors permitting survival 
outside the host cell during transmission of the organism from cell to cell or from host to 
host. After its entry into the host cell EB undergoes morphological changes reorganizing 
to the reticulate body (RB). RB is a larger (Ø 800 –1000 nm), metabolically active form 
of chlamydiae capable of synthesizing DNA, RNA and proteins. Chlamydiae have lost 
their ability to produce their own energy i.e. adenosine triphosphate (ATP) and high-
energy metabolites, hence the term energy-parasite (reviewed by Moulder 1991 and 
Beatty et al. 1994c). In addition, chlamydiae acquire many precursors such as nucleotides 
and amino acids from the host. Compared to EB, RB has a less rigid cell wall and is not 
able to survive outside the host cell (Beatty et al. 1994a). RBs divide by binary fission 
within chlamydial inclusion. After a few rounds of growth and division, RBs reorganize 
condensing to infectious EBs (Figure 2A). Redifferentiation of RBs to EBs starts with 
DNA condensation, which involves histone-like proteins that help pack the chlamydial 
chromosome (Wagar and Stephens 1988, Hackstadt et al. 1991, Tao et al. 1991). 
Redifferentiation is accompanied by the incorporation of MOMP and other outer 
membrane proteins into an outer membrane complex through extensive cross-linking with 
disulfide bonds. The developmental cycle is completed with host cell lysis or exocytosis 
of chlamydial particles allowing EBs to start new infectious cycles. In vitro studies have 
shown that the length of the cycle is approximately 48 –72 hours but it varies as a 
function of the infecting strain, host cell and environmental conditions (Figure 2A; 
reviewed by Beatty et al. 1994a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2. A) Chlamydial developmental cycle, and B) altered developmental cycle (Beatty et al. 
1994a). 
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2.2.1  Molecular composition of chlamydiae 
Both C. trachomatis and C. pneumoniae genomes consist of a more than one million base 
pair (bp) chromosome that has been completely sequenced (Stephens et al. 1998, Kalman 
et al. 1999, http:// chlamydia-www.berkeley.edu:4231). Most C. trachomatis strains have 
a ~7500 bp plasmid. Genes for some essential enzymes encompassing DNA replication, 
repair, transcription, and translation have been identified and a diverse set of genes have 
been found that provide considerable metabolic capabilities for chlamydial growth. 
Systems for nutrient (amino acids, ions etc.) transport from the host have been identified 
(Stephens et al. 1998, Kalman et al. 1999). Also, both genomes sequenced contain genes 
for ADP/ ATP translocases indicating that chlamydiae can acquire ATP from the host cell 
(Hatch 1988). Complete pathways to synthesize and degrade glycogen have also been 
found. Evaluation of putative amino acid sequences of the C. trachomatis and C. 
pneumoniae proteins revealed elements of glycolysis, respiration, and pentose 
biosynthesis as well as open reading frames for previously unknown proteins (Stephens et 
al. 1998, Kalman et al. 1999). Thus, chlamydiae are, in principle, able to produce and 
store high-energy compounds. This was unexpected given the obligate intracellular nature 
of chlamydiae. To what extent these genes and proteins are active in the infected cell 
remains to be settled. 
Comparison of C. trachomatis and C. pneumoniae sequences has revealed certain 
differences in the number of genes. These include genes without homologs between the 
species or in other organisms. C. trachomatis had ~70 genes that were not present in C. 
pneumoniae genome while C. pneumoniae had ~200 genes that were not present in C. 
trachomatis genome. These genes occurred mainly in clusters indicating that they are 
probably responsible for species-specific systems that define their unique biological 
capacities (Stephens 1999). 
Interestingly, chlamydial counterparts for genes of the type III secretion system, that is 
known to be essential basic virulence determinant in microbes (reviewed by Hueck 1998) 
have been discovered and appear to be active in chlamydiae (Hsia et al. 1997, Subtil et al. 
2000, Kim 2001). It is presumed that surface projections on chlamydial EBs described 
twenty years ago by Matsumoto (1981) and Nichols et al. (1985) represent type III 
secretion system (Bavoil and Hsia 1998). Genes for type III secretion system may turn 
out to be important in Chlamydia-host cell interaction if the genes encoding these 
proteins form a system that enables chlamydiae to secrete effector molecules into the host 
cytoplasm that in turn may modulate host’s immune responses. Proteins that are secreted 
by chlamydiae are yet to be identified although there is evidence that they may include 
inclusion membrane-associated (Inc) proteins (Subtil et al. 2001) and Chlamydia outer 
protein N (CopN) (Fields and Hackstadt 2000). In other pathogenic gram-negative 
bacteria type III secretion is usually activated by contact with host cell and specific 
proteins are injected directly into the host cell. The injected proteins disrupt host cell 
signal transduction mechanisms and cytoskeletal arrangements leading to endocytosis of 
the bacterium by epithelial cells or death of professional phagocytes or other events that 
help the bacterium establish a parasite-like relationship (reviewed by Hueck 1998 and 
Plano et al. 2001). In general type III secretion system plays a role in disease process, 
providing bacteria a powerful tool to invade the host. Salmonella and Shigella species use 
the type III secretion system to invade and replicate within the host cell (reviewed by 
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Hueck 1998). In this respect, they represent a similar model of type III secretion system 
that is detected in chlamydiae. 
 
2.2.1.1  Lipopolysaccharide and cytotoxin 
Cell wall of gram-negative bacteria contains lipopolysaccharide (LPS), also called 
endotoxin that is characteristic and essential for the viability of the bacteria. LPS is 
composed of lipid A and hydrophobic and hydrophilic polysaccharide portions. In 
chlamydiae, the polysaccharide part consists of 3-deoxy –D-manno-2 –octulosonic acid 
(KDO) (Dhir et al. 1971, Brade et al. 1986) but lacks the O-chain that is typically found 
in enterobacterial LPS (Brade et al. 1985). KDO contains two antigen determinants, one 
of which is chlamydial genus-specific group antigen. The other is similar to 
enterobacterial Re-type LPS (Nurminen et al. 1983, Brade et al. 1986). Chlamydial LPS 
is inactive in inducing lethal toxicity or pyrogenicity (Brade et al. 1986) and a weak 
inducer of the inflammatory cytokine response (Ingalls et al. 1995). Besides LPS, 
chlamydial cytotoxin with a significant homology to large clostridial cytotoxins has been 
described which may contribute to pathological changes found in chlamydial infections 
(Belland et al. 2001).  
 
2.2.1.2  Outer membrane proteins 
Outer membrane proteins (OMPs) are typically engaged in specific nutrient and 
metabolite acquisition, adhesion to host cells or tissues (Stephens and Lammel 2001). A 
40 kDa MOMP, also known as OmpA, is the most abundant protein in both EBs and RBs 
composing about 60% of total protein mass (Caldwell et al. 1981, reviewed by Brunham 
and Peeling 1994). Its structure varies in the two developmental forms of chlamydiae 
being highly disulfide-linked in EBs and completely reduced in RBs. In all C. 
trachomatis strains the MOMP consists of four variable segments that specify individual 
C. trachomatis serovars flanked by relatively conserved sequences (Zhang et al. 1987b). 
Surface exposure of variable regions makes chlamydial MOMP an obvious target of the 
host’s immune response. Consequently, chlamydial MOMP has been shown to induce 
antibody formation that is directed to both linear and conformational epitopes (Zhang et 
al. 1987a, Zhang et al. 1989, Wolf et al. 2001). Early in vitro studies showed that MOMP 
functions as a tribarrelled porin (Bavoil et al. 1984) allowing ATP to pass through the 
lipid bilayer (Wyllie et al. 1999, Jones et al. 2000). To do this MOMP has to be reduced 
and maintained in a non-cross-linked form, which suggests that only reduced MOMP can 
act as a porin (Bavoil et al. 1984). Thus, it has been speculated that MOMP functions as a 
porin only in the RB form i.e. when chlamydiae are intracellular. 
First OMPs identified in EBs but not in RBs were two cystein-rich proteins OMP3 of 
12 kDa and OMP2 of 60 kDa, also named OmcA and OmcB, respectively. OmcA is a 
lipoprotein, the structure of which resembles murein lipoproteins found in other gram-
negative bacteria. OmcB is processed after transcription to two 60 kDa proteins. Studies 
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suggest that the doublet proteins may function as a pair, but in C. trachomatis only one 
mature OmcB has been detected. The cellular location of the OmcB proteins is 
controversial but it appears that they are located in the periplasm below the inner leaflet 
of the outer membrane in the EB. Furthermore, OmcA is suggested to be anchored in the 
inner leaflet as well through its lipid part (reviewed by Hatch 1999). 
In addition, chlamydial cell wall contains a number of highly polymorphic membrane 
proteins (Pmps), also called putative outer membrane proteins (Pomps) with the 
approximate size of 90 –100 kDa (Campbell et al. 1990, Cevenini et al. 1991, Melgosa et 
al. 1993, Souriau et al. 1994, Longbottom et al. 1998a, Stephens et al. 1998, Knudsen et 
al. 1999, Kalman et al. 1999). Nine Pomp genes (pmpA –pmpI) have been identified in C. 
trachomatis by Stephens et al. (1998). In addition, C. pneumoniae contains as many as 21 
Pomp genes. The function of the Pomps is mostly unknown but of obvious interest 
considering their surface exposition that has been demonstrated in C. psittaci 
(Longbottom et al. 1998b) and in C. trachomatis EBs (Tanzer and Hatch 2001). One of 
the Pomps has been identified as PorB, which functions as a substrate-specific porin 
facilitating efficient diffusion of dicarboxylates across the outer membrane and is thus 
responsible for the transport of essential metabolites for chlamydial growth (Stephens and 
Lammel 2001).  
 
2.2.1.3  Heat shock proteins 
Heat shock proteins (HSPs) are highly conserved proteins present in all organisms from 
bacteria to human. HSPs play central role in cell’s normal processes including their 
function as molecular chaperones during folding, unfolding, assembly and translocation 
of newly synthetized or damaged proteins (Lindquist 1986, Lindquist and Craig 1988). 
They are constitutively expressed in most cells and their production is enhanced in 
response to a wide variety of stimuli such as elevated temperature, anoxia, infection and 
inflammation (Welch 1993, Zugel and Kaufmann 1999b, Zugel and Kaufmann 1999a). 
HSPs are divided into four major families according to their approximate molecular 
weight: HSP90, HSP70 (DnaK in E. coli), HSP60 (GroEL) and small HSPs (Mw 
approximately 10 kDa GroES). HSPs are highly immunogenic (reviewed by Kaufmann 
1990 and Young 1990). Because of their conserved structure (~50% to 60% identical 
residues among HSP60 protein family) the immune response initiated by the microbial 
HSP may also be evoked against self-HSP through cross-reactive epitopes as can be 
concluded from serological studies performed in patients with chronic chlamydial 
infection (Domeika et al. 1998, Witkin et al. 1998).  
CHSP60 is expressed throughout the chlamydial developmental cycle (Engel et al. 
1990, Shaw et al. 2000) and the amount of CHSP60 is increased after the heat shock 
(Engel et al. 1990) and during the course of other unfavourable growth conditions (Beatty 
et al. 1993, Beatty et al. 1994b). Sequencing of the chlamydial genome revealed that it 
contains three different genes coding for proteins with similarity to the HSP60 protein 
family (Stephens 1999). GroEL-1 is linked with the gene encoding GroES (i.e. CHSP10). 
GroEL-2 is not linked with other HSPs. The third gene, GroEL-3, was more distantly 
related but showed tremendous similarity to the 60 kDa HSP family. Comparable 
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multigene families of groEL genes are found also in Mycobacteria (Rinke de Wit et al. 
1992, Kong et al. 1993) and in Bradyrhizobium (Fischer et al. 1993). These three forms 
of CHSP60 may have different though unknown roles during chlamydial developmental 
cycle and possibly in disease pathogenesis. 
CHSP70. Chlamydial HSP70 is constitutively expressed (Birkelund et al. 1990, 
Danilition et al. 1990) and its expression raises after heat stress (Engel et al. 1990). 
CHSP70 is located in the outer membrane complexes of chlamydial EBs (Raulston et al. 
1993) and it is thought to facilitate the entry of the EBs into the host cell (Raulston et al. 
1998), especially in the events following the initial stage of attachment (Raulston et al. 
2002). 
CHSP10. Chlamydial GroES homolog CHSP10 is co-expressed with CHSP60 
(LaVerda and Byrne 1997). Immune response to CHSP10 is associated with the 
pathogenetic sequelae of chronic chlamydial infections (Betsou et al. 1999) and tubal 
occlusion (Spandorfer et al. 1999, LaVerda et al. 2000). 
 
2.3  Chlamydia and disease 
2.3.1  Diseases caused by C. trachomatis 
C. trachomatis infects superficial columnar epithelial cells in various anatomical sites 
such as endocervix, urethra, epididymis, endometrium, fallopian tube, conjunctiva and 
lower respiratory tract (reviewed by Schachter 1999). C. trachomatis has three different 
biotypes: mouse pneumonitis, lymphogranuloma venereum (LGV) and trachoma serovars 
that cause either ocular (serovars A, B, Ba and C) or genital tract infections (serovars D -
K) (Grayston and Wang 1975 and reviewed by Schachter 1999, Mabey and Fraser-Hurt 
2001). Mouse pneumonitis agent is used in animal models to mimic both human genital 
tract and respiratory tract infections. It has proven to be very useful in studying 
chlamydial immunity. 
 
2.3.1.1  Trachoma 
Trachoma is the world’s leading cause of preventable blindness. The ocular infection 
manifests from mild conjunctival lesions (follicular conjunctivitis) to severe forms that 
eventually lead to scarring and blindness. Severe forms develop through repeated or 
persistent infections by C. trachomatis serovars A, B, Ba and C (Taylor et al. 1982, Abu 
el-Asrar et al. 2001). It has been estimated that about 500 million people have had the 
disease. In the developing countries about 7 to 9 million people are estimated to be blind 
because of C. trachomatis infection (WHO, http://www.who.int/). Trachoma is endemic 
mainly in tropical and subtropical countries. Main reservoir of the organism is eye of the 
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infected person, usually a child, and transmission may be potentiated by flies that carry 
infected secretions from person to person (Jones 1974, Emerson et al. 1999). 
 
2.3.1.2  Sexually transmitted infections 
C. trachomatis -infection causes important genital tract diseases in women and men; in 
infants it is the major contributor of inclusion conjunctivitis and pneumonitis. C. 
trachomatis infection is one of the most common sexually transmitted infections (STI), 
with estimated 90 million new cases occurring each year worldwide (WHO, 
http://www.who.int/). It has been estimated that in many populations about 10% of the 
sexually active people are infected with C. trachomatis. Highest incidence of positive 
isolation of chlamydiae is in the age group of less than 25 years (Barnes et al. 1990). The 
incidence gradually decreases with increasing age (Arno et al. 1994). 
Acute genital tract infections manifest in women as urethritis, cervicitis, salpingitis 
(Stamm et al. 1980, Brunham et al. 1984, Dieterle et al. 1998), endometritis (Mårdh et al. 
1981) and pelvic inflammatory disease (PID) (Mårdh et al. 1977, De Punzio et al. 1995, 
Paavonen and Lehtinen 1996). It appears that between 10% -40% of women with C. 
trachomatis infection develop PID (reviewed by Simms and Stephenson 2000 and 
Rogstad 2001). C. trachomatis infection may show mild symptoms but in about half of 
the cases it is asymptomatic (Lan et al. 1995, Rogstad 2001). Repeated infections with 
different or same serovar occur and have been shown to increase the risk for subsequent 
infertility (Patton et al. 1990, Rank et al. 1995, Pavletic et al. 1999). Long-term 
consequences of C. trachomatis infection are associated with ectopic pregnancy (Cates 
and Wasserheit 1991, Gerard et al. 1998a, Barlow et al. 2001), TFI (Punnonen et al. 
1979, Rhoton-Vlasak 2000, Barlow et al. 2001), spontaneous (recurrent) abortions 
(Quinn et al. 1987, Witkin and Ledger 1992), and arthritis (Gerard et al. 1998b). It 
appears that 43% of ectopic pregnancy cases and 25% of TFI cases are due to C. 
trachomatis infection (reviewed by Simms and Stephenson 2000, Rogstad 2001). 
Recently, association of C. trachomatis infection and invasive cervical squamous cell 
carcinoma was found (Koskela et al. 2000, Anttila et al. 2001, Smith et al. 2002). 
In men, C. trachomatis infection causes male urethritis and epididymitis (Berger et al. 
1978, Stamm et al. 1984). Newborn babies can become infected with C. trachomatis 
while passing through the infected birth canal. Inclusion conjunctivitis and chlamydial 
pneumonitis are clinical manifestations of C. trachomatis infection in the newborn and 
have been shown to develop in 18 –50% and 11-20% of cases, respectively (Schachter et 
al. 1982, Alexander and Harrison 1983, Schachter et al. 1986, Numazaki et al. 1989, 
Rogstad 2001).  
LGV differs considerably from other syndromes caused by C. trachomatis. LGV is a 
systemic disease caused by an invasive biovar (serovars L1, L2 and L3) of C. 
trachomatis. LGV infects lymphatic and subepithelial tissues. Although it is an important 
pathogen in some developing countries, it is relatively uncommon in industrialized 
countries. LGV spreads exclusively through sexual contact (reviewed by Schachter 1999).  
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2.3.2  Diseases caused by other chlamydiae 
In the 1980’s an atypical chlamydial strain caused outbreaks of acute lower respiratory 
infections in humans. This strain was originally named TWAR, i.e. Taiwan acute 
respiratory strain and was later renamed as C. pneumoniae by Grayston and colleagues 
(1989). Acute C. pneumoniae causes respiratory tract infections such as sinusitis, 
pharyngitis, bronchitis, but also pneumonia, which can be a serious disease in the 
immunocompromized and in the elderly. C. pneumoniae is one of the most common 
human pathogens (Saikku 2000a). Seroprevalence of C. pneumoniae increases with age 
and 60 –70% of the adult population has antibodies to C. pneumoniae worldwide 
(reviewed by Grayston 1992). Chronic C. pneumoniae infection is associated with 
coronary heart disease, atherosclerosis (reviewed by Saikku 2000a) and adult onset 
asthma (Hahn et al. 1991, Hahn et al. 1996). Evidence is accumulating to suggest that C. 
pneumoniae may predispose to lung cancer (Laurila et al. 1997, Anttila et al. unpublished 
data). 
Both C. psittaci and C. pecorum typically infect animals. C. psittaci causes infections 
in sheep, cattle and cats but mainly in the avian species (ornithosis). Occasionally C. 
psittaci also infects humans causing an atypical pneumonia known as psittacosis. It 
mainly occurs in persons that process or handle birds. Human infection is usually 
acquired through respiratory route and manifests as flu-like (respiratory tract) symptoms 
such as cough, high fever, rigors and headache. Although some fatal cases have been 
reported psittacosis is treatable by antibiotics (tetracycline, erythromycine). C. pecorum 
infects swine, cattle and sheep causing spontaneous abortions. No human infections have 
been reported (reviewed by Schachter 1999).  
 
2.4  Diagnostic techniques to detect clinical chlamydial infection  
In assessing diagnostic tests for C. trachomatis infection it is important to realize that 
different methods measure distinct targets which have different properties and are present 
in different amounts in any given sample. Diagnostics of chlamydial infections include 
direct detection methods, enzyme-immuno assays (EIA) and direct fluorescence assays 
(DFA), nucleic acid hybridization and amplification tests (NAHTs and NAATS, 
respectively), and indirect serological techniques [microimmunofluorescence (MIF) and 
enzyme-linked immuno assays (ELISA)] (reviewed by Black 1997, Battle et al. 2001). 
Major problem in diagnosing acute chlamydial infections is their asymptomatic nature 
and obtaining appropriate specimen for direct detection. Serologic tests are mainly used 
to detect acute respiratory tract infections but they are not useful in the diagnosis of 
chronic chlamydial infections because antibodies are long-lived and a positive result does 
not distinguish between current and past infection (Clad et al. 2000, Tuuminen et al. 
2000). MIF test was developed in the 1970s by Wang and Grayston (1970). It is 
considered the most specific of the serologic tests for chlamydial infections and the only 
serologic test that is able to detect species and serovar-specific responses. The technique 
itself is very laborious and antigens are expensive and available only on a limited basis 
(Dowell et al. 2001). MIF is used also by many laboratories for epidemiological studies. 
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In general, one of the biggest problems lies in diagnosing chronic chlamydial infections 
and markers for chronic infection are still under debate (Black 1997, Boman and 
Hammerschlag 2002). Nevertheless, at present NAATs must be considered the tests of 
choice for diagnosing C. trachomatis infection (Black 1997, Puolakkainen et al. 1998, 
Paavonen and Eggert-Kruse 1999). Table 1 shows an overview of methods used to 
diagnose C. trachomatis infection. 
 
Table 1. Overview of diagnostic methods for detection of C. trachomatis EB or antigens 
in clinical specimens (modified from Caul and Herring 2001). 
Diagnostic test Based on Advantages Disadvantages 
 
Culture Detection of 
viable EBs in the 
specimen 
 
-Only test for medico 
legal work 
-Specificity 
-Preserves viability of 
chlamydiae for additional 
testing 
-Needs skilled laboratory 
staff 
-Sensitivity compared to 
NAATs 
-Needs viable EBs 
-Long time required to 
obtain results 
 
Conventional 
EIAs 
Detection of 
chlamydial LPS 
present outside 
of EBs 
-Simple, high throughput, 
-LPS can be found in 
abundance in specimens 
with low number of 
mature EBs. 
-Standardization 
possible. 
 
-Sensitivities vary greatly 
-Needs confirmation 
Amplified EIAs Detection of 
chlamydial LPS 
present outside 
of EBs 
-Simple, high throughput 
-Good sensitivity and 
specificity 
-Standardization 
possible. 
 
-Needs confirmation 
Direct immuno-
fluorescence 
Detection of 
genus-specific 
(LPS) epitopes or 
species-specific 
epitopes on 
MOMP 
 
-Good for confirmation 
of other tests and 
research. 
-Allows assessment of 
the quality of the 
specimen. 
-Quality of results 
depends on experience of 
technician. 
-Throughput very 
limited. 
NAATs Detection of 
DNA and RNA 
-Highest sensitivity and 
specificity 
-Easy sampling 
-Standardization possible 
-Rapid 
-Needs a lot of laboratory 
space. 
-Contamination is 
constant threat. 
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2.5  Altered chlamydial development 
The productive chlamydial developmental cycle that occurs in normal or optimal growth 
conditions can alter in in vitro culture into slowly growing i.e. persistent development 
with sporadic productions of infectious chlamydial EBs (Figure 2B; Moulder et al. 1980, 
Lee and Moulder 1981). The persistently infected cell cultures has been maintained for 
months (Moulder et al. 1980, Lee and Moulder 1981) or for years (Kutlin et al. 2001). 
Deviations from the typical developmental cycle of chlamydiae has been demonstrated in 
vitro to associate with a development of incomplete chlamydial infection and formation 
of morphologically aberrant RBs (Clark et al. 1982, Shemer and Sarov 1985, Beatty et al. 
1993, Kutlin et al. 2001). In cell cultures chlamydial persistence has been accomplished 
by using penicillin or other antibiotics (Clark et al. 1982, Byrne et al. 1989, Dreses-
Werringloer et al. 2000), nutrient-deficient conditions (depletions of essential amino 
acids such as tryptophan or cysteine) and immune system-regulated factors (cytokines 
like IFN- and tumour necrosis factor (TNF)-) (Coles and Pearce 1987, Coles et al. 
1993, Beatty et al. 1993, Beatty et al. 1995). 
The incomplete chlamydial growth involves non-replicative (or slowly replicating), 
non-infectious but metabolically active stage of development (reviewed by Beatty et al., 
1994 and Ward, 1999). During persistent infection the expression of MOMP is 
significantly reduced in vitro, while the expression of CHSP60 remains at nearly constant 
levels or is enhanced (Beatty et al. 1993, Kinnunen 1997, Gerard et al. 1998c, Dreses-
Werringloer et al. 2000).  
 
2.5.1  The evidence for persistence in animal models and in humans 
Differing from naturally occurring chlamydial infection in humans, animal models are 
useful for evaluating chlamydial persistence in vivo because the time and onset of 
infection can be controlled. Specimens from different tissues are easily available and the 
role of the immune system can be investigated by using knock-out and transgenic animals 
(reviewed by Ward 1999). At present there are few experimental models focused 
specifically on the persistent chlamydial infection or at least on a prolonged infection 
beyond the time at which presence of chlamydiae can no longer be detected by culture. 
Chlamydiae can obviously remain in infected tissue after apparent resolution of infection 
and is detectable with polymerase chain reaction (PCR) techniques (Holland et al. 1992, 
reviewed by Ward 1999). Immunosuppression reactivates chlamydial shedding indicating 
the viability of the organism (Yang et al. 1983, Malinverni et al. 1995, Laitinen et al. 
1996, Cotter et al. 1997). However, a true persistence of chlamydial infections remains 
unverified as the frequency of reactivation was found to fade with time in a mouse model 
of salpingitis (Cotter et al. 1997). 
Animal models have enabled researchers to confirm chlamydial dissemination from a 
local infection into a systematic one involving detection of chlamydial antigen or DNA in 
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deep-seated tissues (reviewed by Ward 1999). The frequency of dissemination and the 
clearance of the infection depends, however, on genotype of immune response genes, 
previous immune sensitization and hormonal status of the host, as well as on the 
virulence of the chlamydial strain, the challenge dose and the route of immunization 
(reviewed by Ward 1999). 
In humans chlamydial persistence has not conclusively been shown partly due to the 
difficulty in discriminating relapse from reinfection. However, there is indirect evidence 
to suggest that this phenomenon may occur during human ocular and genital infections. 
The evidence is based on collected data from studies where chlamydial organisms were 
cultivated from individuals with a disease that occurred years or decades after any 
evidence of active infection, or the chlamydial antigen or nucleic acids were detected in 
the absence of cultivable chlamydiae (Ward et al. 1990, Holland et al. 1993, Toth et al. 
2000, reviewed by Beatty et al. 1994c and Ward 1999). One of the most convincing 
evidence for in vivo persistent chlamydial infection comes from a study conducted by 
Bell et al. (1992) who showed that approximately 35% of infants infected at birth 
remained infected at one year of age. 
In genital tract infections, chlamydiae have been detected three months after 
appropriate treatment in 10% of the patients (Katz et al. 1998) and after postinfectious 
tubal infertility (Patton et al. 1994a). In addition, persistence of C. trachomatis infection 
was shown in cervixes of recurrently infected women by omp1 (MOMP) genotyping 
(Dean et al. 2000). In this study, Dean et al. (2000) studied 45 chlamydial isolates from 7 
women who had had 3 –10 repeated infections with the same serovar over the years. 
Analyses revealed that 5 of the women had identical genotypes at each new episode of 
infection and 2 women had minor amino acid changes after treatment. Interestingly, many 
intervening samples were culture-negative, although chlamydial DNA was detected in 
these samples by ligase chain reaction (LCR). In women with ectopic pregnancy C. 
trachomatis-specific DNA and RNA was detected in the tissue specimens indicating that 
metabolically active bacteria is present (Gerard et al. 1998a). 
 
2.5.2  Suggested mechanisms of chlamydial persistence 
Mechanisms how chlamydiae remain persistent are not known in detail but are probably 
partly explained by the ability of Chlamydia to infect and remain viable in professional 
phagocytes. A plausible molecular mechanism that chlamydiae may use to escape host 
immune responses and remain persistent involves the production of protease-like activity 
factor (CPAFct/cp) that has been demonstrated in both C. trachomatis and C. pneumoniae 
species. CPAFct/cp is secreted into the host cytoplasm where it degrades host 
transcription factor (RFX5) needed for major histocompatibility complex (MHC) gene 
activation (Zhong et al. 2000, Zhong et al. 2001, Fan et al. 2002). This is in accordance 
with the report where C. trachomatis infection decreased the IFN--induced expression of 
MHC molecule on the infected cell (Rodel et al. 1998, Zhong et al. 1999). 
Furthermore, chlamydiae are able to inhibit apoptosis of the host cell by interrupting 
different apoptotic pathways (Fan et al. 1998, Dean and Powers 2001, Coutinho-Silva et 
al. 2001). Apoptosis, also called programmed cell death is genetically programmed 
27 
process in which macromolecules are broken down and released from the cell without 
eliciting inflammation. Apoptosis is triggered by a variety of physiological and stress 
stimuli. It is involved in normal development and tissue homeostasis but it is also a way 
for the host to battle against intracellular micro-organisms. Apoptotic suicide of infected 
host cell can limit the spread of the invading bacteria by delivering it to professional 
phagocytes as has been shown with Mycobacteria (Fratazzi et al. 1997). Thus, 
intracellular bacteria including chlamydiae can benefit by employing anti-apoptotic 
mechanisms in order to evade host’s immune responses and to survive in the host cell for 
prolonged periods of time. 
Also, Chlamydia-infected macrophages in in vitro cultures induce the apoptosis of 
non-infected immune cells such as T-cells (Jendro et al. 2000) which may further 
augment the development of persistent infection. Although the apoptosis of immune cells 
detected in the vicinity of the Chlamydia-infected cells needs confirmation, it is an 
interesting notion in the light of recently discovered capacity of Chlamydia to produce 
cytotoxin (Belland et al. 2001). In addition, studies in our laboratory show that the 
lymphocyte proliferative (LP) responses typically observed after lymphocyte stimulation 
(Surcel et al. 1993) are dramatically reduced in the presence of infected monocytes 
(Airenne et al., unpublished observations). In a mouse model of chlamydial infection 
Perfettini et al. (2002) suggested that IFN- may contribute to pathogenesis of persistent 
Chlamydia infections in vivo by preventing apoptosis of infected cells (Perfettini et al. 
2002). They showed that in addition to producing a persistent chlamydial infection IFN- 
treatment also resulted in inhibition of apoptosis of the infected cells. Instead of directly 
inducing inhibition of apoptosis IFN- may have produced a persistent chlamydial 
infection that induced the anti-apoptotic effect. Dean and Powers (2001) suggested that 
inhibition of host cell apoptosis may enable chlamydiae to form persistent infection while 
locally produced immunoregulatory molecules such as IFN- and interleukin (IL)-10 
could favor the development of aberrant chlamydial form with elevated expression of 
CHSP60 which could sustain inflammation (Dean and Powers 2001). The differential 
expression of MOMP and CHSP60 during normal and altered chlamydial development 
have been known for a long time but a true meaning of this balance in terms of 
chlamydial persistence is not known. 
 
 
2.6  Chlamydia and immune response 
The humoral and CMI responses serve different functions and involve different effector 
mechanisms for generating immunity. Humoral immunity is mediated by secreted 
antibodies, which can neutralize soluble antigens while CMI exerts its function through 
T-cells. Infections caused by intracellular bacteria such as Chlamydia tend to induce CMI 
response. Both antigen-specific T-cells and non-specific antigen presenting cells (APCs) 
contribute to CMI response. Specific cells include CD4+ T-cells secreting different panels 
of cytokines and CD8+ cytotoxic T-lymphocytes (CTLs) (Kuby 1997). 
In vitro studies have shown that antibodies generated during chlamydial infection are 
able to neutralize infectious chlamydiae. Neutralizing antibodies prevent attachment to 
host cell (Byrne and Moulder 1978, Su and Caldwell 1991) or inhibit replication 
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(Caldwell and Perry 1982). In humans a strong antibody response has been detected both 
in serum, genital secretions and tears but conclusive evidence for its role in chlamydial 
elimination or protection against chlamydial infection is lacking (Holland et al. 1993, 
Ghaem-Maghami et al. 1996, Ghaem-Maghami et al. 1997). 
Due to silent nature of chlamydial diseases it is difficult to study development of CMI 
during primary chlamydial infections, although it is plausible that CMI responses take 
place concurrently with antibody response (Hanna et al. 1979, Surcel et al. 1993, Kelly 
and Rank 1997). Bailey et al. (1995) showed that lymphocyte proliferation to chlamydial 
antigens is enhanced in individuals who spontaneously resolve ocular chlamydial 
infection compared to those with persistent ocular disease. In association with human 
genital tract infection, CMI responses against chlamydiae measured as LP responses of 
peripheral blood lymphocytes (PBLs) has been detected (Hanna et al. 1979, Brunham et 
al. 1981, Hanna et al. 1982, Witkin et al. 1993a), but the situation at the site of infection 
i.e. in the genital tract tissue of infected individuals is not known. Role of CD8+ T-cells 
(i.e. CTL) during chlamydial infections has not been as extensively studied as that of 
CD4+ T-cells. CTL response in patients with trachoma was present only in children 
resolving current infection and in adults without scarring indicating that CTL responses 
may be important in the resolution of naturally acquired ocular infection (Holland et al. 
1997). Nevertheless, despite the presence of Chlamydia-specific immune response, 
animals and humans do become reinfected.  
The MHC molecules are central in the development of antigen-specific immune 
responses. In order to a T-cell to recognize an antigen it must be processed and presented 
in the context of a MHC or human leukocyte antigen (HLA) molecule, as it is called in 
humans. MHC class I molecules bind and present peptides derived from endogenous 
antigens that have been processed within the cytoplasm of the cell (e.g. normal cellular 
proteins or viral and bacterial proteins produced within infected cell). They present these 
peptides to CD8+ T-cells. HLA class II molecules bind and present peptides derived from 
exogenous antigens that have been internalized and processed within the endocytic 
pathway. They present peptides to CD4+ T-cells. Because MHC molecules function as 
antigen presenting structures, the particular set of MHC molecules expressed by a certain 
individual influences the T-cell repertoire responding to different antigens. For this reason 
MHC partly determines whether an individual is able to respond to antigens of an 
infectious organism and therefore MHC molecules have been associated with disease 
susceptibility (reviewed by Kuby 1997, Maksymowych and Kane 2000, Witkin et al. 
2000). 
 
2.6.1  Cytokines and T-cell response 
After recognition of MHC-peptide complex by T-cell receptor the T-cell is activated. 
Activation is seen by the production of cytokines, a group of low-molecular weight 
proteins. Cytokines assist in regulating immune effector cells i.e. they function as 
messengers of the immune system (reviewed by Kuby 1997). In the mid 80’s Mosmann et 
al. (1986) suggested that murine T-cells could be divided into two functionally different 
subsets according to the cytokines they produce. Type 1 (Th1) T-cells produce mainly 
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IFN (and IL-2, TNF-, TNF-) while type 2 (Th2) T-cells produce IL-4 (and IL-5, IL-
6, IL-10, IL-13 and possibly IL-9) (reviewed by Curfs et al. 1997). Thus, type 1 response 
is defined as a strong cellular immune response with normal or increased levels of IL-2, 
IFN, TNF- and/or IL-12 while type 2 response is defined as an impaired cellular 
response with an increase in one or more B-cell activities and an increase in the level of 
IL-4, IL-5, IL-6, IL-10 and/or IL-13. Importantly, in this definition the emphasis is on the 
relative predominance of type 1 or type 2 cytokines and not on the absolute dichotomy of 
either type of cytokine (Lucey et al. 1996). Main leukocyte sources of type 1 and type 2 
cytokines are shown in Table 2 (Lucey et al. 1996). A simple division of T-cells to Th1 –
Th2 type cells has not been demonstrated in humans. Evaluation of different cell types 
according to cytokines they produce have shown cells capable of producing both Th1 and 
Th2-type cytokines. These cells have been determined as intermediate or Th0 type cells. 
 
Table 2. Main leukocyte sources of type 1 and type 2 cytokines (Lucey et al. 1996)  
                                               Cytokine(s) 
Cell source Type 1 Type 2 
 
 
CD4+ T-cell 
 
IL-2, IFN-, IL-12, TNF- 
 
IL-4, IL-5, IL-6, IL-10, IL-13 
CD8+ T-cell IL-2, IFN- IL-4, IL-5, IL-10 
NK cell IFN., TNF-  
Monocyte/ 
macrophage 
IL-12 IL-6, IL-10 
B cell IL-12, TNF- IL-6, IL-10 
Dendritic cell IL-12  
Neutrophil IL-12  
Mast cell  IL-4, IL-5, IL-6 
Eosinophil  IL-4, IL-5, IL-6 
   
 
Suppressor T cells (or regulatory T (Tr) cells) are able to suppress immune response in 
vivo and they are strong producers of IL-10. They are also able to inhibit harmful 
immunopathological responses directed against self or foreign antigens through 
suppression of other T-cells. Tr-cells occur naturally as a subset of CD4+ T-cells. Animal 
studies provide convincing evidence that specialized Tr-cells capable of controlling 
autoimmune responses exist as part of the T-cell repertoire in normal animals. Although 
the activation of Tr-cells depends on antigenic stimulation once activated these cells are 
able to suppress both CD4 and CD8 positive cells in an antigen-nonspecific manner. The 
mechanism of Tr cell action probably involves inhibition of IL-2 production by normally 
responsive T-cells (reviewed by Maloy and Powrie 2001). 
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2.6.1.1  Cytokines and Chlamydia 
Outcome of chlamydial infection is influenced by the interaction and balance of pro- and 
anti-inflammatory cytokines present at the site of infection. Two cytokines, IFN and 
IL-10, are especially important for immunity to chlamydial infections. In the murine 
system CD4+ T-cell mediated immune response alone is enough to resolve primary 
chlamydial infection and to provide immunity against reinfection. Protection is mainly 
mediated through the action of IFN (Ramsey and Rank 1991, Rank et al. 1992, 
Igietseme et al. 1993, Su and Caldwell 1995, Van Voorhis et al. 1996). In a recent study 
with mice Morrison et al. (2000) showed that the co-operation of CD4+ T-cells and B-
cells are important in recall immune responses in mice while CD8+ T-cells were not 
needed for protective immunity. On the other hand, resolution of secondary chlamydial 
infection in immune mice does not necessarily need CD4 and CD8+ cells but indicate 
that additional effector immune responses have a role in resistance to chlamydial genital 
tract reinfection (Morrison and Morrison 2001). These mechanisms may include TNF- 
(Williams et al. 1997). Protective role for CD8+ T-cells may be underestimated since 
mouse is the only animal in which it has been studied. 
In in vitro experiments IFN- has been closely linked with the development of 
persistent chlamydial infection through chlamydial growth inhibition. IFN- induces the 
production of the enzyme indoleamine 2,3-dioxygenase (IDO), which degrades 
tryptophan, an essential amino acid for chlamydial development (Summersgill et al. 
1995). However, sensitivity to IFN varies significantly among different serovars of C. 
trachomatis (Perry et al. 1999, Morrison 2000). Downregulation of the Th1 (IFN-) 
response at the site of inflammation during infection may lead to prolonged infection and 
inflammation (Yang et al. 1996). In addition, IFN- induces the expression of HLA-DR 
molecules in epithelial cells (Tabibzadeh et al. 1986), which can function as non-
professional APC and become a target of immune response. 
Emerging evidence in rodents suggests that prolonged (persistent?) infection is 
mediated by IL-10 (Yang et al. 1999, Igietseme et al. 2000). This is due to the ability of 
IL-10 to down-regulate the expression of Th1-type cytokines. The situation with 
chlamydial genital tract infections resembles that of reactive arthritis (ReA) which is 
triggered by an infection by intracellular bacteria such as Yersinia, Chlamydia or 
Salmonella. Effective elimination of these bacteria is mediated through the action of Th1-
type cytokines (reviewed by van Roon et al. 2001) while the symptoms and progression 
of the disease is associated with a predominance of Th2-type cytokines in the synovial 
tissue of ReA patients (Yin et al. 1997). 
 
2.6.1.2  Cytokine gene polymorphisms and disease 
In vivo production of the cytokine is influenced by polymorphisms in the promoter region 
of the specific cytokine gene (Turner et al. 1997, Conway et al. 1997, Westendorp et al. 
1997, Crawley et al. 1999, Reynard et al. 2000, Gibson et al. 2001, Hahn et al. 2001, 
Hulkkonen et al. 2001, Poli et al. 2001, Cox et al. 2001). Westendorp et al. (1997) found 
that approximately 60% of the variation in TNF- and 75% of the variation in IL-10 
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production was due to genetic differences. Thus, it is not surprising that different cytokine 
gene polymorphisms have been associated with the outcome of a disease. In chlamydial 
diseases Conway et al. (1997) showed an association of scarring trachoma with 
polymorphism in the TNF- gene promoter and elevated TNF- levels in tear fluid 
(Conway et al. 1997). In another trachoma study, Mozzato–Chamay et al. (2000) found 
an association between the disease and the IL-10 -1082GG genotype, although the 
association was detected only in one out of five ethnic groups. 
 
2.6.1.3  Innate immunity 
Innate host response in chlamydial diseases has not been studied thoroughly. According 
to literature, innate host response plays a role in reducing the number of infectious EBs 
during initial stages of the infection, but it may also have an important role in the actual 
disease pathogenesis (reviewed by Bavoil et al. 1996 and Rank and Bavoil 1996). The 
primary responses seen in animal models and in humans comprise infiltration of 
polymorphonuclear leukocytes (PMNs), which clearly reduce or even eliminate 
infectivity of chlamydiae (Yong et al. 1986, Register et al. 1986, Register et al. 1987). 
Despite the chlamydiatoxic effect of PMNs many chlamydial organisms probably survive 
because of their ability to attach to susceptible epithelial cells and gain rapidly access to 
the intracellular environment (reviewed by Bavoil et al. 1996). 
Animal models with mouse pneumonitis have shown an increase of IFN producing 
cells in the genital tract (Tseng and Rank 1998) and in the respiratory tract (Williams et 
al. 1993) of infected animals early in the disease course. Increase in IFN production 
was not affected by the elimination of CD4+ T-cells suggesting that IFN was produced 
by the natural killer (NK) cells (Tseng and Rank 1998, Williams et al. 1993). 
TNF- has also been detected during chlamydial infection (Shemer-Avni et al. 1988, 
Kaukoranta-Tolvanen et al. 1996, Darville et al. 2001b). TNF- eliminates chlamydiae in 
the early stage of infection in a murine model of lung (Williams et al. 1990) and tubal 
infection (Darville et al. 1997). During chronic or persistent chlamydial infection TNF- 
seems to play a major role in the tissue damage and scarring at least in trachoma 
(Conway et al. 1997). Whether TNF- exerts its effect directly (chlamydiatoxic) or 
whether it potentiates homing of various inflammatory cells to the site of infection 
remains to be elucidated. In addition to IFNand TNF, nitric oxide (NO) is produced 
and may be one of the non-specific mechanisms by which chlamydiae are cleared, at least 
in murine model of chlamydial infection (Rottenberg et al. 1999, Rottenberg et al. 2000, 
Ramsey et al. 2001). 
 
2.6.2  60 kDa Heat shock protein as an antigen 
As discussed earlier (2.2.1.3) HSPs are highly conserved proteins that function as 
molecular chaperones under normal physiological conditions. They are important 
antigens inducing both humoral and CMI responses. In Mycobacterium, HSP60 has been 
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described as an immunodominant antigen because a considerable part of the in vitro 
activated T-cells seem to be targeted against HSP60 (Kaufmann et al. 1987). The HSP60-
specific immune response is associated with several infectious diseases including 
tuberculosis, arthritis and chlamydial infections as well as in certain autoimmune diseases 
(reviewed by Kaufmann and Schoel 1994, Gaston 1998, Zugel and Kaufmann 1999b, 
Neuer et al. 2000 and Kinnunen et al. 2001). In addition to the infectious and 
autoimmune diseases, HSP60-specific antibodies have been detected in healthy 
individuals as well (Pockley et al. 1999). This has led to a suggestion that the HSP60-
directed immune response is induced by frequent contact with low virulence or non-
pathogenic organisms, which drives and maintains the immune response especially 
against the conserved regions of HSP-molecule and confers at least partial protection 
against pathogenic organisms invading the host (reviewed by Kaufmann and Schoel 
1994). 
Because of high amino acid and structural homology between HSP60s in different 
species, the immune response initially generated against the microbial HSP60 can 
eventually be targeted against cross-reactive epitopes in self-HSP60 molecule. The 
activation of self-HSP60-specific immune responses is generally considered to be 
detrimental for the well-being of the host and associated with a shift from protective 
immune response into pathological one (reviewed by Kaufmann and Schoel 1994). In C. 
trachomatis-induced diseases enhanced antibody and CMI response to CHSP60 are 
typically detected in the patients (Tables 3 and 4). CHSP60 is considered as the antigen 
mediating the immunopathogenesis of persistent chlamydial infections such as TFI and 
scarring trachoma (Morrison et al. 1989a, Morrison et al. 1989b, Patton et al. 1994a, 
Patton et al. 1994b). Antigenic structure of HSP60 has been studied in detail. 
Nevertheless, data on human responses against specific B-cell or T-cell epitopes of 
CHSP60 is limited. However, antibodies to specific B-cell epitopes of CHSP60 have been 
characterized in infants with chlamydial pneumonitis (Paavonen et al. 1994) and in 
women with PID (Domeika et al. 1998). Detection of self-HSP60-specific antibodies 
(Domeika et al. 1998, Witkin et al. 1998) or activation of self-HSP60-specific T-cells in 
peripheral blood (Witkin et al. 1994) in the patients suggests that the 
immunopathogenesis of chronic chlamydial diseases may involve self-HSP60-targeted 
immunity.  
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Table 3. Examples of humoral response to CHSP60 in association with different 
chlamydial diseases in humans. 
 
 
Disease association  
 
Reference 
 
 
PID 
 
Peeling et al. 1997 
PID Domeika et al. 1998  
PID, ectopic pregnancy Wagar et al. 1990  
PID, occluded tubes Eckert et al. 1997 
Ectopic pregnancy Sziller et al. 1998  
Chronic salpingitis, TFI Dieterle and Wollenhaupt 1996 
TFI Toye et al. 1993 
TFI Persson et al. 1999  
TFI Ault et al. 1998 
Infertility Arno et al. 1995  
Infertile couples Witkin et al. 1998 
Infertile women Freidank et al. 1995  
Trachoma Peeling et al. 1998,  
Trachoma Hessel et al. 2001 
 
 
 
Table 4. Examples of cellular responses to CHSP60 and human HSP60 in association 
with chronic chlamydial diseases in human. 
 
 
CMI response to 
 
Disease association 
 
Reference 
 
 
CHSP60 
 
Salpingitis 
 
Witkin et al. 1993b  
CHSP60 and human 
HSP60 
 
Salpingitis Witkin et al. 1994  
Human HSP60 Spontaneous abortion, 
endometriosis 
 
Kligman et al. 1998  
CHSP60 Trachoma Bailey et al. 1995  
CHSP60 Trachoma Holland et al. 1993  
CHSP60 Trachoma Holland et al. 1996  
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The functional role of HSP60-reactive T-cells in terms of cytokine secretion has been 
studied in association with Yersinia- or Chlamydia-induced ReA in which T-cell 
activation has been detected against both bacterial and self-HSP60 molecule (Hermann et 
al. 1991, Mertz et al. 1998). Studying function of synovial fluid derived T-cells in 
patients with Yersinia-induced ReA, Mertz et al. (1998) demonstrated that self-HSP60 
directed T-cell responses involve a production of Th2-type cytokines. They suggested that 
the Th2-type cytokine milieu could be responsible for the impaired host defence against 
the microbe and lead to bacterial persistence within the synovium and eventually lead to 
pathological changes seen in the joints. Similar to ReA, activation of CHSP60-specific 
Th2-type cells was demonstrated in individuals with scarring trachoma but not in age- 
and sex-matched controls (Holland et al. 1996) further supporting the hypothesis that 
chlamydial pathogenesis involves activation of Th2 cells. 
On the other hand, early rheumatoid arthritis (RA) is linked with lower and less 
frequently detected CMI responses to mycobacterial HSP60 compared to healthy controls 
(Ramage and Gaston 1999) suggesting that inflammatory conditions such as RA might be 
associated with defective regulatory responses to bacterial HSP60. In juvenile RA T-cell 
proliferative responses to self-HSP60 were associated with the disease remission 
(Prakken et al. 1996). van Roon et al. (1997) suggested that expression of self-HSP60 
molecules might activate regulatory Th2-type cells, which can cause suppression of T-
cells that induce arthritis (i.e. Th1-type cells). Further support for this has been provided 
by Macht et al. (2000) who showed that RA was less severe in those patients whose 
HSP60-stimulated PBLs produced Th2-type cytokine response. Taken together data from 
studies with experimental models of arthritis and chlamydial infections as well as from 
humans have shown that HSP60 have a potential to trigger the production of Th2-type 
cytokines. 
 
2.6.3  Immunopathogenic responses in chlamydial infections 
In addition to elimination of and protection from chlamydial infections CMI responses to 
Chlamydia are involved in the pathogenesis of chlamydial diseases (reviewed by Loomis 
and Starnbach 2002). This notion is originally based on animal studies, which showed 
that sensitization of guinea-pigs with a detergent soluble extract of chlamydial EBs 
accelerated accumulation of mononuclear lymphocytes in the regions of ocular 
inflammation (Watkins et al. 1986). In a comparable study with monkeys, Taylor et al. 
(1987) showed that the follicular response was observed only in C. trachomatis-
immunized but not in naive animals. Later Morrison and coauthors (1989a, 1989b) 
demonstrated that a 57 kDa protein, identified as CHSP60, is the active component and 
responsible for the DTH response in trachoma. Experimental studies in the monkey 
“pocket” model of salpingitis have further supported the role of CHSP60-specific T-cells 
in the immunopathogenesis of salpingitis (Patton et al. 1994b). Pigtailed monkeys were 
sensitized by inoculation of live C. trachomatis organisms into subcutaneous pockets 
containing salpingeal autotransplants. When recombinant CHSP60 was injected into such 
pockets of previously sensitized monkeys, a typical DTH reaction was detected.  
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Serological studies have implicated that C. trachomatis has immunodominant proteins 
such as MOMP and CHSP60 that most of the host’s immune response is directed at. 
During persistent infection the expression of CHSP60 is enhanced while the expression 
of MOMP is maintained at a low level (Beatty et al. 1993, Gerard et al. 1998c, Dreses-
Werringloer et al. 2000). This is indirectly seen as appearance of CHSP60-specific 
antibodies in the patient’s serum (Table 3). Appearance of CHSP60 antibodies in the 
patients’ serum are associated with repeated or persistent C. trachomatis infections (Table 
3). However, the role of the CHSP60 antibodies remains unclear since antibody to 
CHSP60 could also be mere indicator of chronic infection. Studying patients with ectopic 
pregnancy Yi et al. (1993) have found CHSP60-specific antibodies that are cross-reactive 
with self-HSP60 suggesting that these antibodies are possibly playing role in disease 
pathogenesis. Prolonged or repeated exposure to CHSP60 or to both human and 
chlamydial HSP60 could result in braking down of immunological tolerance and lead to 
self-HSP60-directed immunity through cross-reactive T- and B- cell epitopes.  
The immunopathogenesis studies in humans have mainly focused on the role of CMI 
in disease pathogenesis. Holland et al. (1993) showed that scarring trachoma is linked to 
markedly depressed LP response to chlamydial antigens and involves downregulation of 
Th1 activity and IFN- response (Holland et al. 1996). They further showed that Th2-type 
of response was detected after stimulation of the patients’ PBLs with CHSP60 while 
MOMP induced Th1-type (i.e. IFN) response. Similar to the humoral responses, LP 
reactivity to CHSP60 is linked with repeated or chronic C. trachomatis infection (Beatty 
et al. 1993, Witkin et al. 1993a). Studying LP responses of circulating lymphocytes in 
vitro, Witkin et al. (1993a) demonstrated positive LP responses to CHSP60 more often in 
patients with salpingitis than in healthy controls. The responses were directed to 
chlamydial peptides that share substantial homology with human i.e. self-HSP60 (Witkin 
et al. 1994). More recently, Witkin et al. (1998) reported that cell-mediated immunity to 
human HSP60 is associated with a history of spontaneous abortion. 
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3 Aims of the present study 
Purpose of this study was to investigate the immunopathological mechanisms of C. 
trachomatis–induced infertility in women. To better understand the relationship between 
CHSP60 and T-cells in the inflamed tissue, we established Chlamydia-specific T-
lymphocyte lines (TLLs) from the obstructed fallopian tubes of infertile women (TFI) 
and from endometrial biopsies of patients with acute PID. The following questions were 
asked:  
 
1) What is the relative role of chlamydial antigens in modulating immune responses in 
TFI (I)? 
 
2) Are in vivo activated T-cells responding to C. trachomatis or CHSP60 present in PID 
and TFI patients’ tissue (II)?  
 
3) What is the role of CHSP60 in modulating the immune response in TFI (III)? 
 
4) What is the role of HLA alleles and cytokines in the regulation of the host T-cell 
response to C. trachomatis (IV)  
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4 Materials and Methods 
Detailed description of materials and methods has been given in the original articles (I-
IV). 
4.1  Study subjects and specimens 
The study population consisted of 22 consecutive patients with a clinical diagnosis of 
PID, who attended the Department of Obstetrics and Gynecology at the University 
Hospital of Helsinki, between January 1997 –June 1998. The PID patients underwent an 
operative laparoscopy that confirmed the diagnosis of acute PID in 14 of the 22 (64%) 
patients. The laparoscopic diagnosis of PID was based on commonly accepted visual 
findings (Tukeva et al. 1999). The TFI group consisted of 57 women attending the 
infertility clinic of the same hospital because of tubal occlusion with or without severe 
tubo-ovarian adhesion during January 1997 –April 2000 (Papers II and III, Table 5). An 
additional study population consisted of 28 women with other infertility factor, such as 
endometriosis or ovulation disorder, 23 women with unexplained infertility, and women 
partners of 25 couples with male factor infertility (control group for immunological 
analyses in Papers I and IV, Table 5). The control group for HLA genotyping and IL-10 
promoter gene polymorphism analysis (Paper IV) consisted of 61 Finnish female adults 
(age range 23 to 69 yrs) who were collected in the context of another study on HLA-
association and Helicobacter carriage (Karhukorpi et al. 1999). HLA allele frequencies 
of the control group were found to be similar to those in general Finnish population 
(Ikäheimo et al. 1996). 
Endometrial biopsy specimens were obtained from the PID (n=14) and TFI patients 
(n=22) for histology, immunohistochemistry, and lymphocyte cultures (II). In addition, 
fallopian tube tissue specimens were obtained from 6 infertility clinic patients who 
underwent elective salpingectomy because of hydrosalpinx formation (II, III). Tissue 
specimens for morphological studies were fixed in 10% neutral buffered formalin and 
embedded in paraffin. Specimens for lymphocyte cultures were immersed in tissue 
culture medium as described in Paper II. Heparinized blood samples were drawn from all 
subjects for immunological analyses and kept at room temperature for no longer than 24 
hours prior to the separation of PBLs (I-IV). 
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4.2  Chlamydial strains and antigens 
C. trachomatis serovars E (ATCC VR-348B), F (ATCC VR-346) and L2 (ATCC) were 
propagated in McCoy-cells and C. pneumoniae Kajaani 7 was propagated in HL-cells. 
EBs were purified using conventional Urografin (Schering AG, Berlin, Germany) density 
gradient centrifugation. Purified EBs were either formalin-inactivated (Surcel et al. 1993) 
or suspended in sucrose-phosphate-glutamic acid (SPG; 0.2 M sucrose, 3.8 mM KH2PO4, 
6.7 mM Na2HPO4 x 2H2O, 5 mM glutamic acid; pH 7.4) buffer and stored in small stock 
aliquots at -70C until used. The number of chlamydial inclusion forming units (IFU) was 
determined by infecting McCoy- or HL-cells with serially diluted EB stock suspension. 
Chlamydial inclusions were stained with chlamydial genus-specific fluorescein 
isothiocyanate (FITC)-conjugated antibody (Sanofi Pasteur Redmond, WA, USA) at 72 
hours of incubation and counted using fluorescent microscope. Recombinant CHSP60 
(LaVerda et al. 2000) was a generous gift from Dr. RP Morrison (Montana, USA) and 
contained <0.03 ng/ml of endotoxin as determined by Limulus assay. 
 
4.3  Measurement of serum antibodies 
Serum samples for the detection of C. trachomatis-specific immunoglobulin (Ig)G (I, IV) 
and IgA (IV) antibodies were diluted 1:10 and studied using commercially available 
synthetic C. trachomatis-specific peptide-based EIA kits (Labsystems, Helsinki, Finland) 
according to manufacturer’s instructions. Results were obtained by calculating the mean 
absorbance of duplicate samples at 450 nm. OD 	 1 was used as positive cut-off level as 
recommended by the manufacturer. 
 
4.4  Immunohistochemistry 
For histological examination, paraffin sections of endometrial and fallopian tube tissue 
specimens were routinely stained with hematoxylin and eosin. T-cell populations were 
stained either on paraffin or cryostat sections with primary antibodies as follows: 
CD45RO (T memory cells, clone UCHL1, Dako a/s, Glostrup, Denmark), CD4 (T helper 
cells, clone SK3, Becton Dickinson Immunocytometry Systems, San Jose, CA, USA), 
CD8 (T suppressor cells, clone SK1, Becton Dickinson), CD15 (monocytes, clone MMA, 
Becton Dickinson), CD20 (B cells, clone L26, Dako) and CD25 (IL-2 receptor, clone 
2A3, Becton Dickinson). Detailed description of immunohistochemical stainings is 
presented in Paper II. The presence of C. trachomatis in genital tract tissues was 
visualized by direct immunofluorescence microscopy of paraffin sections as earlier 
described by Rantala and Kivinen (1998). 
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4.5  Peripheral blood lymphocyte and T-lymphocyte cultures 
PBLs were isolated from heparinized blood by Ficoll-Paque
 (Pharmacia Biotech, 
Uppsala, Sweden) density gradient centrifugation. Cells were suspended in RPMI-1640 
medium (Sigma, St.Louis, MO, USA) containing 10% heat-inactivated human AB serum 
(Finnish Red Cross, Helsinki, Finland) for the LP assay (I, II, IV), or 5% fetal calf serum 
(FCS) for cytokine analyses (I, II, IV). 
C. trachomatis–specific TLLs were cultured from the endometrial biopsy and fallopian 
tube tissue specimens as described in Paper II. Briefly, IL-2 receptor expressing T-cells 
representing in vivo activation of these cells were propagated by adding IL-2 (10% 
vol/vol; Lymphocult, Biotest, Germany) into the culture medium and incubated for 10 
days in 5% CO2 atmosphere at 37C. Half of the IL-2 containing medium was changed 
every third day. Growing T-cells were further augmented by stimulation with chlamydial 
EB antigen three times before antigen specificity tests were performed. Proliferating T-
cells were suspended in RPMI-1640 medium containing 10% (vol/vol) IL-2 
(Lymphocult) and cloned by the limiting dilution method as described previously (Halme 
et al. 1997 and Paper III). Briefly, 0.5 blast cells per well were cultured for 10 days with 
phytohemagglutinine (PHA; 2 µg/ml) and fresh irradiated PBL (10 000 cells/well) as the 
APC in a total volume of 20 l. The expanding T-lymphocyte clones (TLCs) were 
restimulated with mitogen (PHA) three to four times for periods of ten days before they 
were used in the antigen specificity tests. Half of the IL-2 containing culture medium was 
changed every third day, but no later than four days before the antigen specificity test.  
 
4.6  Antigen specificity of the lymphocytes 
The PBL (5 x 104 cells/well) proliferative reactivity to chlamydial EB antigens (C. 
trachomatis strains E, F or L2, and C. pneumoniae K7) and CHSP60 was studied in vitro 
according to Surcel et al. (1993) and as described in Papers I and IV. Pokeweed mitogen 
(PWM, Gibco, Paisley, UK; 12.5 g/ml) was used as a positive control mitogen in each 
experiment. The antigen specificity of the TLL and TLC was tested by culturing 20 000 
cells in the presence of 20 000 irradiated autologous APC and chlamydial antigens 
according to Papers II and III. Results are expressed as stimulation indices (SI = mean 
cpm in the presence of the antigen divided by mean cpm in its absence) for triplicate 
cultures. Tetanus toxoid was used as control antigen. TLLs or TLCs giving a positive 
response to tetanus toxoid were omitted from the analysis. For PBL cultures SI > 2.5 was 
used as a positive value, while for TLL and TLC cultures SI > 3 was used as a positive 
cut-off value because the frequency of antigen-specific cells is clearly higher among 
TLLs and TLCs than that among the PBLs. 
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4.7  Surface antigens of the lymphocytes 
Surface antigens of the lymphocytes were studied by double immunofluorescence flow 
cytometric analysis. Cultured lymphocytes were stained using phycoerythrin (PE)-
conjugated anti -CD4 and FITC-conjugated anti -CD8 monoclonal antibodies (Caltag 
Lab., San Francisco, USA) and analyzed by FACScan (Becton Dickinson and Co., 
Mountain View, CA, USA). 
 
4.8  Antigen or mitogen induced cytokine secretion 
Cytokine production was induced by incubating PBL cells (I, II, IV), TLL (II) or TLC 
(III) with or without chlamydial antigens or mitogen (PHA). Cytokine analyses were 
performed on supernatants from lymphocyte cultures using commercially available 
enzyme-linked immunosorbent assay kits (ELISA; DuoSet
 human IFN-, IL-10, IL-
12p40 (IV) and IL-4 (II); R & D Systems, Minneapolis, USA; PeliKine CompactTM 
human IL-10 (III) ELISA, CLB, Amsterdam, Netherlands, DuoSetTM Human IFN-, 
Genzyme Diagnostics, Cambridge, MA, USA; II, III and Pharmingen QuantigenTM 
Human IL-5 Set, San Diego, California, USA; II) according to the manufacturer’s 
instructions. PBLs were considered positive when the concentration of cytokine (pg/ml) 
in the presence of antigen was at least twice that in the absence of antigen. PBL responses 
were considered Th1-dominant when the ratio of IFN-to IL-10 was 	 2, Th2-dominant 
when the ratio was  0.5. 
 
4.9  Analyses of HLA class II genotypes 
HLA-DQA1 and HLA-DQB1 genotyping was performed using PCR-SSP method 
(Olerup et al. 1993). Genomic DNA for analyses was extracted from the peripheral 
leukocytes using proteinase K digestion in 10% SDS and 7.5 M guanidine-HCl and 
precipitated with ethanol. Primers and PCR conditions are described in Materials and 
Methods in Paper IV. 
 
4.10  Detection of interleukin-10 promoter gene polymorphism 
IL-10 promoter gene polymorphism of a single nucleotide at position -1082 (A/G) was 
determined using sequence-specific oligonucleotide primers in a bidirectional PCR 
amplification method according to Karhukorpi and Karttunen (2001). The primers and 
PCR conditions are as described in Paper IV (Materials and Methods and Table I in Paper 
IV).  
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4.11  Statistical Analyses 
SPSS for Windows 9.1 statistical software (SPSS Inc. Chicago, Illinois, USA) was used 
to perform Mann-Whitney U-test (I, II), Wilcoxon Signed-Rank test (I), and to calculate 
Spearman’s correlation (I) and 2 test (I, II). Fisher’s exact test was used to compare 
proportions between groups. Confidence intervals were calculated by CIA program (IV). 
The significance of the HLA association results was corrected using the Bonferroni 
correction multiplying the p value by the factor 22 (8 tests for HLA-DQA1 and 14 tests 
for DQB1). Spearman correlation coefficient was used to test the association between 
lymphocyte responses to different antigens (IV). 
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5 Results 
5.1  C. trachomatis-specific antibody and lymphocyte proliferative 
responses 
C. trachomatis-specific IgG antibodies indicative of past C. trachomatis infection were 
detected more often in TFI patients (31 of 56; 55%) than in other groups (18 of 74; 24%, 
p<0.001; Paper I and Table 5). 
 
Table 5. Selected characteristics of the study population of 133 females of infertile 
couples. 
   Positive a Positive LP b  
   anti-chlamydial response to  
Infertility group  Mean age IgG titer CTR EB CHSP60 
 N yrs (range) No. (%) No. (%) No. (%) 
      
TFI 57 34 (22-41) 31/56 (55%)** 49/57  (86%) 20/57 (35%) 
Other female factor 28 33 (24-37) 8/27   (30%) 23/28  (82%) 9/28   (32%) 
Unexplained 23 34 (25-40) 2/23   (9%) 15/23  (65%) 4/23   (17%) 
Male factor 25 32 (23-39) 8/24   (33%) 17/25  (68%) 4/24   (17%) 
 
Statistical comparison between TFI and all other groups (combined): **p<0.001 
a) OD value at 450 nm  1  
b) Stimulation index >2.5  
TFI: tubal factor infertility; CTR EB: Chlamydia trachomatis elementary bodies 
 
LP responses of the PBLs were assessed with chlamydial EB antigens and CHSP60. 
Positive LP responses (SI > 2.5) to C. trachomatis EB antigen were more common in the 
TFI group (49 of 57; 86%) than in the control group (17 of 25; 68%; Paper I and Table 5) 
but the difference did not reach statistical significance. Median SI to C. trachomatis EB 
was significantly higher in the TFI group (SI 11.5, range 0.4 to 247.6) than in the control 
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group (SI 3.9, range 0.2 to 74.6; p<0.005). There were no statistically significant 
differences in median SI between TFI group and other female factor group (SI 6.9, range 
1.1 to 64.7) or between TFI group and unexplained infertility group (SI 7.7, range 0.3 to 
59.8). Presence of C. trachomatis-specific IgG antibodies and the LP responses did not 
correlate. 
LP responses to CHSP60 were highly variable (median SI 1.4, range 0.2 to 141) with 
no statistically significant differences between the study groups. The largest variance was 
seen in the TFI group. Positive responders (SI > 2.5) were found in 20 of 57 (35%) TFI 
patients compared to 4 of 24 (17%) controls (Paper I and Table 5) but the difference did 
not reach statistical significance. TFI patients who had a negative LP response to the EB 
antigen did not respond to the CHSP60 either. C. trachomatis-specific IgG antibodies 
were detected in 10 of 20 (50%) of TFI patients who had a positive LP response to 
CHSP60 compared to none of four controls with positive LP response to CHSP60. 
 
5.2  Histopathology and immunohistochemistry 
Endometrial biopsies from 13 PID patients and from 22 TFI patients were available for 
histopathological examination. Fallopian tube tissue samples were available from 6 TFI 
patients. Routine histology showed endometritis with plasma cell infiltrations in 7 of 13 
(54%) PID patients and in 4 of 22 (18%) TFI patients (Paper II). The total number of 
lymphocytes varied remarkably, the median number of lymphocytes/ 10 high-power field 
(HPF) was clearly higher in patients with plasma cell endometritis than in the non-
endometritis patients (613; range 137 to 2220 vs. 91; 27 to 890; p<0.001). Chronic 
salpingitis with mucosal atrophy was found in 5 of 6 TFI patients. 
Overall, the number of inflammatory cells was greater in the PID patients’ endometrial 
specimens than in the TFI patients’ specimens. The majority of the endometrial 
lymphocytes in the PID group were T memory cells (Paper II and Table 6). T-cells were 
found only occasionally in the endometrial specimens of the TFI patients and no T-
memory cell predominance was noted. Most of the T-memory cells were CD4+ T-cells in 
all tissues (Paper II and Table 6). On the other hand, fallopian tube tissue specimens of 
the TFI patients contained equal amounts of inflammatory cells compared to endometrial 
specimens of the PID patients. This suggests that in the TFI patients the inflammation 
was restricted in the fallopian tubes, while in the PID patients the inflammatory response 
took place in the endometrium. 
 
5.3  Characterization of T lymphocyte lines 
IL-2 induced growth of T-cells as TLLs more frequently in the PID patients’ endometrial 
specimens (8 of 14; 57%) than in the TFI patients’ endometrial specimens (4 of 22; 18%, 
p<0.05). In addition, IL-2 supported T-cell growth in 4 of 6 (67%) fallopian tube tissue 
specimens obtained from TFI patients indicating that in vivo activated T-cells are present 
in the inflamed tissue of both patient groups. 
Table 6. Mononuclear lymphocyte subsets (number of positive staining cells in 10 high power fields) in the female 
upper genital tract tissue specimen from acute PID patients and TFI patients. 
 
Tissue 
 
T-memory 
cells 
 
Monocytes
 
B-cells 
 
CD4+ T-
cells 
 
CD8+ T-
cells 
 
CD4/CD8 
 
 
PID patients’ 
Endometrium
 
 
n=13 
 
 
n=13 
 
 
n=13 
 
 
n=4 
 
 
n=4 
 
 
n=4 
   Median (Range) 330 (39-
1500) 
66 (16-
1100) 
22 (9-
220) 
445 (110-
1100) 
115 (5-
310) 
7 (1.6-22) 
 
TFI patients’       
Endometrium n=20 n=20 n=19 n=2 n=2 n=2 
   Median (Range) 72 (22-400) 17 (10-30) 11 (0-
54) 
185 (102-
268) 
91.5 (43-
140) 
2.1 (1.9-2.4)
 
TFI patients’ 
      
Fallopian 
tube 
n=6 n=6 n=6 n=4 n=4 n=4 
   Median (Range) 370 (121-
700) 
28 (9-700) 9 (9-45) 280 (9-500) 108 (5-
175) 
2.2 (1.1-5.7)
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Three of 4 TLLs established from the endometrial specimens of the TFI patients and all 4 
TLLs established from the fallopian tube tissue specimens of TFI patients responded to 
C. trachomatis EB antigen. Only 2 of 8 TLLs established from the endometrial specimens 
of PID patients responded to the EB antigen. Furthermore, the median LP responses of 
the TLLs established from fallopian tube specimens of the TFI patients were significantly 
higher than median responses of the endometrial TLLs (median 16 822 cpm, range 11 
668 to 24 187 vs. 1502; 194 to 2035; p<0.001, Paper II). Background proliferation in the 
absence of antigen ranged from 31 to 608 cpm. CHSP60 was recognized by all 4 TLLs 
derived from the fallopian tube tissue specimen of the TFI patients. Thus, in patients with 
chronic chlamydial infection and its complications the CMI response is directed to both 
chlamydial EB antigen and CHSP60. 
 
5.4  Characterization of T lymphocyte clones 
To further evaluate the role of CHSP60-specific T-cells among the TLLs established from 
the inflamed fallopian tube tissue, 229 TLCs were successfully grown from three of five 
women with TFI. Antigen specificity of the TLCs was tested with C. trachomatis EB 
antigen. Seventy-seven (34 %) of the 229 TLCs were positive (SI > 3) to the recalled C. 
trachomatis EB antigen (median SI 20.7, range 3 to 580). 
Antigen reactivity of the 77 C. trachomatis EB responsive TLCs was further 
characterized by studying LP responses to C. pneumoniae EB antigen and to CHSP60 
(Paper III and Figure 3). Positive LP responses (SI > 3) to C. pneumoniae EB were found 
in 52 of 77 (67%) C. trachomatis-specific TLCs (median SI 11.6; range 3.3 to 235) 
suggesting that their target epitopes were Chlamydia genus-specific. CHSP60 induced 
positive proliferative responses in 26 of 77 (34%) TLCs (median SI 6.8; range 3 to 926). 
Twenty-three of the 26 (88%) CHSP60-specific TLCs responded also to both C. 
trachomatis and C. pneumoniae EB (Paper III and Figure 3). 
 
Fig. 3. Distribution of TLCs recognizing a target epitope on C. trachomatis EB only (CTR), on 
both C. trachomatis and C. pneumoniae EB (CTR + CPN), on C. trachomatis EB and 
chlamydial heat shock protein 60 (CTR+CHSP60) and on C. trachomatis EB, C. pneumoniae 
EB and CHSP60 (CTR+CPN+CHSP60) (Paper III). 
CTR+C HSP 60
(n=3)
CTR +C PN
(n=29)
CTR
(n=22)
CTR+CP N+
CH SP 60
(n=23)
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5.5  Cytokine analyses of the peripheral blood lymphocytes 
Secretion of pro-inflammatory cytokines (IFN- and IL-12) and anti-inflammatory IL-10 
was studied from culture supernatants of chlamydial antigen stimulated PBLs. Median 
IFN- secretion induced by C. trachomatis EB antigen was greater in the TFI group (280 
pg/ml,; range <10 to 8914 pg/ml) than in the control group (median 18 pg/ml, range <10 
to 193 pg/ml; p<0.01; Paper I and Table 7). In addition, median IL-10 production in 
response to EB stimulation was significantly lower in the TFI group (median 138 pg/ml, 
range <3 to 6498 pg/ml) compared to controls (1150 pg/ml, <3 to 5529 pg/ml, p<0.001; 
Paper I and Table 7). No differences were observed in the IL-12 secretion after 
stimulation with EB antigen (data not shown).  
 
Table 7. Median production of IFN- and IL-10 (pg/ml) by PBLs stimulated with C. 
trachomatis EBs (CTR EB) or CHSP60 antigen. 
 PBL stimulated IFN- IL-10 
Group   with Median (range) Median (range) 
    
TFI CTR EB 280 (<10 -8914)* 138   (<3 –6498)** 
(N=57)  CHSP60 32   (<10 –7483)** 1764 (<3 –7245)** 
    
Other female CTR EB  154 (<10 -1026) 871  (<3 –4270) 
Factor (N=28) CHSP60 <10  (<10 –31) 68    (<3 –2959) 
    
Unexplained 
(N=23)  
CTR EB 
CHSP60 
120 (<10 -638) 
<10  (<10) 
673   (<3 –6870) 
177   (<3 –3247) 
    
Male factor CTR EB 18   (<10 -193) 1150 (<3 –5529) 
(N=25)  CHSP60 <10  (<10) 345   (<3 –2388) 
    
Statistical comparison between TFI and Male factor group: 
* p<0.01; ** p<0.001 
 
 
CHSP60-stimulated PBL cultures produced significantly higher median amounts of IFN-
 (median 32 pg/ml, range <10 to 7483 pg/ml) and IL-10 (median 1764 pg/ml, range <3 
to 7245 pg/ml) in the TFI group, compared to the IFN- (median <10 pg/ml, range <10 
pg/ml) and IL-10 (median 345 pg/ml, range <3 to 2388 pg/ml) production found in the 
control group (p<0.001; Paper I and Table 7). 
PBL cytokine responses were classified into Th1, Th2 and Th0 type responses 
according to the ratio of secreted IFN- and IL-10 (Paper I and Table 8). IFN- secretion 
i.e. Th1 type response dominated after stimulation with C. trachomatis EB antigen in 33 
of 46 (72%) women with TFI compared to only 3 of 15 (20%) controls. On the contrary, 
after stimulation with CHSP60 secretion of IL-10, i.e. Th2-type response dominated in 20 
of 49 (41%) women with TFI. The difference of the cytokine distribution following EB 
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and CHSP60 stimulation within the TFI group was statistically significant (p<0.001; 
Paper I and Table 8). 
 
Table 8. Th1 vs. Th2 distribution (number of positive specimens/ responders) of 
peripheral blood lymphocyte response to C. trachomatis elementary bodies (CTR EB) or 
CHSP60 by infertility group. 
 Cytokine response to    
 CTR EB  CHSP60  
Group Th1 a Th2 b Th1 Th2 
 
TFI 
 
33/46 (72%)* 
 
3/46   (7%)* 
 
7/49   (14%)* 
 
20/49  (41%)* 
Other female 
factor 
8/13   (62%) 0/13   (0%) 3/15   (20%) 4/15    (27%) 
Unexplained 6/9     (67%) 0/9     (0%) 0/11   (0%) 1/11    (9%) 
Male factor 3/15   (20%) 3/15   (20%) 1/16   (6%) 4/16    (25%) 
 
ALL 50/83 6/83 11/91 29/91 
 
Statistical comparison between CTR EB and CHSP60 induced responses: *p<0.001 
a) ratio of IFN- to IL-10  2 
b) ratio of IFN- to IL-10 > 0.5 
 
5.6  Cytokine analyses of the C. trachomatis-specific T-lymphocyte 
lines and clones 
Cytokine production profile was analyzed from the culture supernatants of 5 
representative C. trachomatis-specific TLL using ELISA. After stimulation with PHA all 
TLL secreted high quantities of IFN- (median 1007 pg/ml, range 765 to 1080 pg/ml), 
whereas IL-5 production varied considerably (median 779 pg/ml, range 91 to 1034 
pg/ml). Two TLL produced high amounts of IFN-, suggesting a Th1-dominant response. 
Two TLLs produced comparable amounts of both IFN- and IL-5 indicative of both type 
1 and type 0 T-cell reactivity. No IL-4 secretion was detected. 
Forty-five randomly selected C. trachomatis-specific TLCs were characterized by 
studying their ability to produce IFN- and IL-10 in response to the chlamydial antigens. 
After stimulation with C. trachomatis EB antigen secretion of both IFN- and IL-10 was 
observed in 37 of 45 (82%) TLCs. Comparison of these TLCs showed an IL-10-dominant 
(Th2) response in 22 (59%) and an IFN--dominant (Th1) response in 8 (22%) of 37 
TLCs (p<0.01). Production of both IL-10 and IFN-, (i.e. a Th0-type response) was found 
in 7 of 37 (19 %) TLCs. 
The distribution of 14 CHSP60-reactive TLCs according to Th1- and Th2-dominant 
cytokine response was evaluated as well. Seven (50%) TLCs showed a Th2-dominant 
response, two (14%) showed a Th1-dominant response, and five (36%) showed a Th0-
response (both IL-10 and IFN- were found). 
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5.7  HLA-DQA1 and HLA-DQB1 alleles 
Eight HLA-DQA1 alleles and 14 HLA-DQB1 alleles were found among 52 TFI patients 
and 61 control women. The allele frequencies were comparable between the groups 
(Paper IV and Table 9). The frequencies of HLA-DQA1*0102 and HLA-DQB*0602 
alleles were slightly, although not significantly, higher among the TFI patients (0.31 and 
0.23) than among the controls (0.16 and 0.10, respectively; Paper IV and Table 9). 
Twenty-two of 52 (42%) TFI patients had HLA-DQB1*0602 compared to 10 of 61 (16%) 
control women (p=0.04, Paper IV and Table 9). 
 
5.8  IL-10 promoter gene polymorphism and HLA-DQ alleles 
The allele frequency of IL-10 -1082A was 0.58 in the TFI patients and 0.51 in the 
controls, and corresponding frequencies of the IL-10 -1082G allele were 0.42 and 0.49, 
respectively. IL-10 -1082AG heterozygotes were found in 21 of 51 (41%) TFI patients 
and in 32 of 61 (52%) controls. IL-10 -1082AA homozygotes were found slightly more 
often among the TFI patients (19 of 51; 37%) than among the controls (15 of 61; 25%, 
Paper IV and Figure 4A), but the difference was not statistically significant. 
A clear association of IL-10 –1082 AA homozygocity and both the HLA-DQA1*0102 
and HLA-DQB1*0602 alleles were found among the TFI patients. The combination of 
DQA1*0102, DQB1*0602 alleles and IL-10 –1082AA was found significantly more 
often among the TFI patients than among the controls (0.18 and 0.02, respectively; 
p=0.005).  
Table 9. Distribution of HLA-DQA1 and HLA-DQB1 alleles in 52 women with tubal factor infertility (TFI) and in 61 control subjects. 
 TFI   Controls    
HLA-DQA1 
allele 
Number of 
positive subjects 
Number of 
alleles 
(2n=104) 
Allele frequency 
(n=52) 
, 
Number of 
positive subjects 
Number of 
alleles 
(2n=122) 
Allele 
frequency 
(n=61) 
Uncorrected p
Allele 
frequency 
0101 15 16 0.15 21 21 0.17 0.711 
0102 28 32 0.31 18 20 0.16 0.010 
0103 12 14 0.13 12 12 0.10 0.395 
0104 2 2 0.02 8 8 0.07 0.113 
0201 4 4 0.04 4 4 0.03 1.00 
0301 8 10 0.10 19 20 0.16 0.134 
0401 5 5 0.05 14 14 0.11 0.072 
0501 19 21 0.20 22 23 0.19 0.800 
HLA-DQB1 
allele 
       
0201 15 16 0.15 18 19 0.16 0.969 
0301 6 8 0.08 9 9 0.07 0.929 
0302 7 9 0.09 15 15 0.12 0.376 
0303 4 4 0.04 4 4 0.03 1.00 
0401 0 0 0.00 1 1 0.01 1.00 
0402 5 5 0.05 12 12 0.10 0.153 
0501 18 19 0.18 22 24 0.20 0.789 
0502 1 1 0.01 0 0 0.00 0.278 
0503 0 0 0.00 7 7 0.06 0.016 
0601 0 0 0.00 1 1 0.01 1.00 
0602 22 24 0.23 10 12 0.10 0.007 
0603 12 14 0.13 11 11 0.09 0.288 
0604 3 3 0.03 7 7 0.06 0.349 
0608 1 1 0.01 0 0 0.00 0.460 
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Fig. 4: Distribution of IL-10 –1082 AA, AG and GG genotypes (A) in 51 TFI patients and in 
61 control women, and in TFI subgroups with patients who have negative or positive (B) cell-
mediated response to C. trachomatis EB antigen (SI-Ctr neg and SI-Ctr pos) or chlamydial 
heat shock protein 60 (SI-HSP60 neg and SI-CHSP60 pos). p=0.046 when comparing the 
number of IL-10 AA genotypes between TFI patients with positive or negative SI-CHSP60. 
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5.9  C. trachomatis-specific immune response, HLA-DQ alleles and IL-
10 promoter gene polymorphism 
The possible association of humoral and/ or CMI responses to C. trachomatis with HLA-
DQA1 and HLA-DQB1 alleles was analyzed for the ten most frequently found HLA 
alleles (DQA1* 0101, 0102, 0103, 0301, 0501 and DQB1* 0201, 0302, 0501, 0602, 
0603; Paper IV and Table 9). Distribution of the HLA alleles did not differ between the C. 
trachomatis -IgG positive and negative or between C. trachomatis EB or CHSP60 LP 
positive and negative TFI patients (Figure 4B and data not shown). 
On the other hand, TFI patients with a positive LP response to CHSP60 had IL-10 –
1082A allele significantly more often (0.72) than TFI patients with a negative CHSP60 
response (0.46, p=0.01, Paper IV and Figure 4B). Furthermore, IL-10 -1082 AA 
homozygotes were detected more frequently in the CHSP60-responsive than in the non-
responsive TFI patients (52% vs. 25%, p=0.046; Paper IV and Figure 4B). Five of 23 
(22%) TFI patients with positive LP response to CHSP60 were positive also for IL-10 -
1082AA and for the HLA-DQA1*0102 and HLA-DQB1*0602 alleles, whereas only 1 of 
61 (2%) controls had this combination (p=0.005). No significant associations between the 
IL-10 polymorphism and C. trachomatis antibody response or LP response against 
chlamydial EBs were found. 
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6 Discussion 
6.1  Lymphocyte proliferative responses to chlamydial antigens 
Chronic C. trachomatis infection is an important etiological factor in TFI (Paavonen and 
Lehtinen 1996, Paavonen 1998). C. trachomatis-specific antibody response is generally 
investigated when evaluating a cause for infertility and a positive antibody response is 
often accepted as a marker of Chlamydia-related TFI (Mol et al. 1997, Chernesky et al. 
1998). However, little is known about the role of C. trachomatis-specific immune 
responses in laparoscopically verified tubal occlusion. Whether and to what extent 
grouping of patients on the basis of detectable Chlamydia humoral immunity results in 
misclassification of TFI patients is not known. In our study, C. trachomatis-induced 
immune responses, either humoral or CMI were detected more often in the women with 
TFI than in the controls (women in the male factor infertility group). The proportion of 
TFI patients with C. trachomatis-reactive antibodies was about 50 %, which is 
comparable to corresponding analyses reported by others (Veenemans and van Der 
Linden 2002). It is also in accordance with the low specificity of C. trachomatis antibody 
testing in screening TFI (Mol et al. 1997). According to our results positive LP response 
to C. trachomatis was frequently found in TFI group. One may argue that the LP assay is 
less specific than the antibody test as a marker of past C. trachomatis infection and may 
reflect immunization with any chlamydial species. However, we have previously 
observed that LP responses are clearly higher to C. trachomatis than to C. pneumoniae in 
women with PID related diseases (unpublished observations) while in “normal” 
population C. pneumoniae-induced LP responses dominate (Halme et al. 1998, von 
Hertzen et al. 1998, Halme et al. 2000). This suggests that in a selected population of 
subjects i.e. women with TFI, a positive LP response can be considered as a sign of past 
C. trachomatis infection. 
When evaluating CMI responses against chlamydial EB antigen and CHSP60 we 
found that the PBLs of TFI patients responded more often to CHSP60 than those of the 
controls which is in accordance with a previous study on women with salpingitis (Witkin 
et al. 1993a). Witkin et al. (1994) has also shown that the CHSP60-induced PBL response 
is directed at conserved epitopes of the HSP60-molecule (Witkin et al. 1994). 
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Development of CHSP60-directed LP responses requires multiple episodes of salpingitis 
(Witkin et al. 1994). Alternatively, the CHSP60-specific LP responses may appear during 
persistent infection but there is no experimental evidence for this assumption. In our 
study, seropositivity did not overlap with the LP reactivity against the CHSP60 antigen 
since half of the CHSP60 responders had no C. trachomatis-specific antibodies. It is 
tempting to think that the CHSP60-induced LP responses are even more specific than 
antibody analyses to identify subjects with previous C. trachomatis infection although the 
specificity may be limited to chronic chlamydial infection. Also, it is possible that 
CHSP60-induced responses cannot differentiate chronic disease sequelae caused by C. 
trachomatis or C. pneumoniae and crossreactivity with HSP60 molecules from other 
micro-organisms can not be excluded.  
While an enhanced CMI response to CHSP60 is linked with adverse disease sequelae 
in women with PID related diseases (Witkin et al. 1993a, Witkin et al. 1994, Kligman et 
al. 1998), the situation seems opposite in patients with scarring trachoma. Scarring 
trachoma is linked with markedly depressed LP response to chlamydial antigens (Holland 
et al. 1993) and subjects recovering from ocular chlamydial infection had enhanced CMI 
responses to chlamydial antigens including MOMP and CHSP60 (Bailey et al. 1995). It 
is difficult to know whether the discrepancy between the C. trachomatis-induced CMI in 
PID related diseases and trachoma is real. It could reflect differences in the Chlamydia 
burden and induced immunity in the control groups of different studies. In trachoma 
endemic areas nearly all subjects have acquired ocular chlamydial infection at some stage 
of their life. The risk for acquiring chlamydial genital infection is much smaller 
especially in the Western world and the controls are more likely to have no immunity to 
C. trachomatis. 
 
6.2  Immune responses of tissue derived T-cells to chlamydial antigens 
To get evidence for the attendance of C. trachomatis activated T-cells in the inflamed 
tissue we established Chlamydia-specific TLLs (Paper II) and TLCs (Paper III) from the 
obstructed fallopian tubes of TFI patients and from endometrial biopsies of acute PID 
patients. C. trachomatis was recognized as a specific target antigen by 25% of the TLL 
obtained from the PID patients and by 75% of the TLL obtained from the TFI patients. 
Inflammation detected as infiltration of mononuclear cells was found more frequently in 
the fallopian tube tissue. Thus, C. trachomatis when present in the fallopian tube tissue 
(Thejls et al. 1991, Campbell et al. 1993, Patton et al. 1994a) participates in maintaining 
the tissue inflammation (Paavonen and Lehtinen 1996, Stamm 1999, Cohen and Brunham 
1999) and may thereby provoke the tissue injury and eventual tubal occlusion seen in TFI 
patients. 
We found that the CHSP60 was recognized only by the TLL originating from the TFI 
patients but not by TLL originating from the PID patients. One third of the C. 
trachomatis-specific TLCs derived from TFI patients’ inflamed fallopian tube tissue 
recognized CHSP60. Since chlamydial EB contains a wide variety of proteins capable of 
eliciting CMI responses (Halme et al. 1997), the frequency of the CHSP60-reactive TLCs 
in the inflamed fallopian tube tissue is high. This is the first direct evidence for a 
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dominant role of CHSP60 as the T-cell stimulating antigen in TFI and correlates with 
experimental (Morrison et al. 1989a) and human studies (Witkin et al. 1993b, Toye et al. 
1993, Arno et al. 1995, Eckert et al. 1997, Peeling et al. 1997, Domeika et al. 1998), 
which have linked the pathogenetic reactions to chlamydial infection with CHSP60. 
Recently, Goodall et al. (2001) showed that CHSP60-induced LP responses of PBLs or 
proportions of CHSP60-specific TLCs derived from synovial fluid were equal or higher 
than those detected with OMP2. This is noteworthy since OMP2 is the second most 
abundant protein in chlamydial membrane. Further support for CHSP60 capability of 
eliciting strong CMI responses comes from C. trachomatis-induced ReA where CHSP60 
responding T-cells were found in synovia-derived cells (Gaston et al. 1996). In addition, 
in patients with Yersinia-triggered ReA Yersinia-reactive T-cells respond both to Yersinia 
antigens and to mycobacterial and the human HSP60 (Hermann et al. 1991, Mertz et al. 
1998). 
 
6.3  Cytokine responses against Chlamydia 
The immuno regulative role of CHSP60-induced CMI in TFI was evaluated by analyzing 
the secretion and balance of IFN- and IL-10, the two cytokines suggested to influence 
the outcome of chronic chlamydial infection (Wang et al. 1999, Yang et al. 1999). 
Positive LP response of PBLs to C. trachomatis EB was associated with a dominant 
secretion of pro-inflammatory IFN-, which is needed for clearance of chlamydial 
infection (Rank et al. 1992, Igietseme et al. 1993, Van Voorhis et al. 1996). 
Although PBL from all patients secreted IFN- when stimulated with the EBs, the 
greatest variation in IFN- production occurred in the TFI group. The variation in the in 
vitro IFN- secretion is comparable to the results of Arno et al. (1990) who studied IFN- 
in endocervical secretion of C. trachomatis infected women. The levels of IFN-, 
however, varied considerably among individuals (from high to undetectable levels). 
Unfortunately, we can not draw conclusions regarding the IFN- secreting capacity of the 
chlamydial EB-activated lymphocytes in vivo. It is also noteworthy that the link between 
IFN- concentration and elimination of C. trachomatis cannot be judged simply by 
measuring cytokine concentrations in clinical specimens. This is to a great extend due to 
fact that C. trachomatis strains differ in sensitivity to inhibition by IFN- (Perry et al. 
1999, Morrison 2000). 
We found that CHSP60 induced higher secretion of IL-10 in TFI patients than in the 
controls. Debattista et al. (2002) has recently reported that women with PID and those 
with a history of multiple C. trachomatis infections show reduced IFN- responses to 
CHSP60. They also found that the CHSP60-induced IL-10 secretion was somewhat 
higher in the patients compared to uninfected controls. In an analogous study in 
individuals with severe scarring trachoma, CHSP60 has also been reported to induce Th2-
type immune response (Holland et al. 1996).  
Using tissue derived TLCs we found that a majority of the CHSP60-specific TLCs 
produced IL-10, Th2-type cytokine. We were not able to investigate the physiological 
cytokine concentrations in the fallopian tubes. However, it is tempting to speculate that 
the high frequency of IL-10 producing TLCs derived from the TFI patients’ fallopian tube 
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tissue reflects their capacity to reduce the effect of IFN- (Mosmann and Moore 1991) 
induced by C. trachomatis infection. 
The immune response to CHSP60 is generally associated with chronic chlamydial 
infections (Witkin et al. 1993a, Witkin et al. 1994) and CHSP60 has been shown to 
induce marked inflammatory reactions in animals (Morrison et al. 1989a, Patton et al. 
1994b, Van Voorhis et al. 1997) and in humans (Kol et al. 1999). However, the potential 
of HSP60s to trigger release of immunosuppressive cytokines has also been demonstrated 
(Holland et al. 1996, Mertz et al. 1998). Holland et al. (1996) showed that CHSP60 
induces activation of IL-4 and IL-10 mRNA expression in patients with scarring trachoma 
but not in C. trachomatis immunized healthy controls. We found that more than half of 
the tissue derived TLCs produced IL-10 when stimulated with CHSP60. We did not study 
reactivity of the TLCs to human HSP60, but some of the TLCs might be cross-reactive 
and recognize an epitope also on human HSP60. C. pneumoniae-specific TLCs derived 
from atherosclerotic plaques do recognize both CHSP60 and human-HSP60 (Mosorin et 
al. 2000).  
Enhanced IL-10 secretion, i.e. a shift towards the Th2-type immune response is 
associated with lymphocyte activation against self-HSP60 in mice (Yi et al. 1997) and 
leads to delayed resolution of chlamydial infection (Yang et al. 1996). In addition, Mertz 
et al. (1998) showed in Yersinia-triggered ReA that TLCs responding to both human- and 
bacterial HSP60 produced Th2-type cytokine response while TLCs responding only to 
bacterial HSP60s produced Th1-type cytokine response. Thus, responses to self-HSP60 
might lead to partial or temporary down-regulation of an effective bacterial clearance 
through Th1 response and facilitate microbial persistence. 
 
6.4  Chlamydia-induced immune response and HLA 
Immune response to CHSP60 plays an important role in chlamydial TFI (reviewed by 
Paavonen and Lehtinen 1996, Neuer et al. 2000, Kinnunen et al. 2001). Experimental 
studies with mice implicate that host’s genetic make-up partly determines whether a 
pathological response develops against Chlamydia (Zhong and Brunham 1992, Yang et 
al. 1996, Darville et al. 1997, Stagg et al. 1998, Darville et al. 2001b, Darville et al. 
2001a). In a macaque model of PID Lichtenwalner et al. (1997) showed that 
susceptibility or relative resistance to rapid formation of tubal adhesions is correlated 
with MHC class I alleles (Lichtenwalner et al. 1997). However, only a few studies have 
elucidated the impact of HLA antigens and disease susceptibility in human chlamydial 
infections (Mabey et al. 1991, Conway et al. 1996, Kimani et al. 1996, White et al. 1997, 
Gaur et al. 1999, Cohen et al. 2000, Abu el-Asrar et al. 2001). Although most of these 
studies suggest potential role for HLA class I and II antigens in chlamydial disease 
pathogenesis, no clear or unambiguous results have been obtained. Thus, C. trachomatis-
associated PID has been linked with HLA-A31 (Kimani et al. 1996) and on the other 
hand with HLA-DQA1*0401 and DQB1*0402 alleles (Gaur et al. 1999).  
According to our results considerable proportions of C. trachomatis-specific T-cells 
established from the inflamed fallopian tube tissue are targeted to CHSP60 and produce 
IL-10. TFI patients had slightly more often HLA-DQA1*0102 and DQB1*0602 alleles 
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compared to controls. We also found that women with TFI had LP responses to CHSP60 
in association with HLA-DQA1*0102 and DQB1*0602 alleles suggesting that these 
HLA alleles may present CHSP60-derived epitopes. The possible association of these 
alleles with TFI may reflect an association with other HLA genes such as HLA- 
DRB1*1501 because of linkage disequilibrium between these genes. These three alleles 
are strongly associated with DR2 antigen. Interestingly, White et al. (1997) have reported 
an association between HLA-DR16, one subtype of DR2 antigen, and scarring trachoma. 
We found a possible association of HLA-DQA1*0102 and DQB1*0602 alleles and TFI 
in Finland while in Nairobi an association of C. trachomatis seropositivity and HLA- 
DQA1*0101 and DQB1*0501 alleles in TFI was reported (Cohen et al. 2000). 
Geographic differences in C. trachomatis strains, the permissive nature of HLA 
molecules in binding available epitopes after processing or the criteria for patient 
definition are possible explanations for the discrepancy. 
We did not compare IL-10 production and IL-10 promoter gene polymorphisms, but 
IL-10 –1082 AA genotype is associated with lower production of IL-10 compared to –
1082 GG genotype (Turner et al. 1997). This contradicts our earlier results suggesting 
that CHSP60 induced increased production of IL-10 in TFI patients (I-III). On the other 
hand, Nieters et al. (2001) did not find an association of a given genotype and in vitro 
production of IL-10 (Nieters et al. 2001). Thus, the relationship between in vivo 
production of a cytokine and single nucleotide polymorphisms is not clear and may 
involve interactions of several single nucleotide polymorphisms (Eskdale et al. 1998, 
Eskdale et al. 1999, Helminen et al. 1999, Gibson et al. 2001) and differencies between 
ethnic groups are likely (Mozzato-Chamay et al. 2000). 
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7 Conclusions 
C. trachomatis infection is the major cause of sexually transmitted diseases especially in 
the industrialized countries. Acute infections are often asymptomatic or subclinical and 
are thus left untreated. Reinfections with the same or different serovars are common 
indicating that individual immunity is short-lived and serovar-specific. Long-term 
consequences of repeated or chronic infections include scar formation of the inflamed 
fallopian tube tissue and subsequent infertility due to occlusion of the fallopian tubes. 
Only a proportion of the infected women develop scarring and TFI, however, suggesting 
that genetic factors modulate the immune responses and thereby the pathogenesis of 
chronic chlamydial disease. Major chlamydial component associated with disease 
sequelae is CHSP60. It has been shown to modulate immune responses both in animals 
and in humans during chronic chlamydial infection.  
Our aim was to elucidate the role of CHSP60-induced immune response in women 
with TFI by studying C. trachomatis-specific TLLs and TLCs derived from the inflamed 
endometrial and salpingeal tissue specimens. Our results show that CHSP60 antigen is 
recognized by T-cells present in the peripheral blood and in the inflamed fallopian tube 
tissue of TFI patients. In addition, CHSP60 seems to induce Th2-type cytokine responses 
in C. trachomatis-specific T-cells and may thereby down-regulate IFN- mediated 
immune response that is needed to eliminate chlamydiae. Furthermore, the CHSP60-
specific CMI response was associated with HLA-DQA1*0102 and HLA-DQB1*0602 
alleles and IL-10 –1082 AA genotype in the TFI patients. In genetically predisposed 
persons the production of an improper cytokine response i.e. Th2-type cytokines in 
response to CHSP60 or self-HSP60 could lead to a cycle of persistent and apparent 
infections as well as continued antigenic stimulation and inflammation. End result would 
then be structural damage of the fallopian tube tissue and infertility. In conclusion, we 
showed that the characteristics of the immune response to CHSP60 involve genetic 
regulation and possibly collaboration between HLA and IL-10 genes. Whether HLA and 
IL-10 genes can be used as markers of the risk for developing TFI should be determined 
with larger study populations. 
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